

1   **Monocytes, Macrophages, Dendritic Cells and Neutrophils: an**  
2   **update on lifespan kinetics in health and disease**

3   Amit A Patel<sup>1\*</sup>, Florent Ginhoux<sup>2,3,4\*</sup> and Simon Yona<sup>5\*</sup>

4  
5   <sup>1</sup>Inserm U1015, Gustave Roussy, Villejuif, France <sup>2</sup>Singapore Immunology Network (SIgN),  
6   Agency for Science, Technology and Research (ASTAR), Singapore, Singapore <sup>3</sup>Shanghai  
7   Institute of Immunology, School of Medicine, Shanghai Jiao Tong University, Shanghai, China  
8   <sup>4</sup>Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Centre,  
9   Singapore, Singapore <sup>5</sup>Institute of Dental Sciences, Faculty of Dental Medicine, Hebrew  
10   University, Jerusalem, Israel

11   \* Correspondence: [Amitashok.Patel@gustaveroussy.fr](mailto:Amitashok.Patel@gustaveroussy.fr), [Florent\\_Ginhoux@immunol.a-star.edu.sg](mailto:Florent_Ginhoux@immunol.a-star.edu.sg), [s.yona@mail.huji.ac.il](mailto:s.yona@mail.huji.ac.il)

13   **Abstract**

14

15   Phagocytes form a family of immune cells that play a crucial role in tissue maintenance and  
16   help orchestrate the immune response. This family of cells can be separated by their nuclear  
17   morphology into mononuclear and polymorphonuclear phagocytes. The generation of these  
18   cells in the bone marrow, to the blood and finally into tissues is a tightly regulated process.  
19   Ensuring the adequate production of these cells and their timely removal, is key for both the  
20   initiation and resolution of inflammation. Insight into the kinetic profiles of innate myeloid  
21   cells during steady state and pathology will permit the rational development of therapies to  
22   boost the production of these cells in times of need or reduce them when detrimental.

23

24   **Introduction**

25

26   Under healthy physiological conditions, the human body maintains a steady number of  
27   leucocytes by means of cell proliferation, differentiation, survival and cell death. The bone  
28   marrow is regarded as the primary hematopoietic factory for the production of the majority  
29   of adult immune cells. Following their egression into the circulation and tissues, these cells  
30   will fulfil their purpose and then eventually die, only to be replaced by newly produced  
31   younger cells thought to keep the immune system alert at all times. The importance of this  
32   fine balance can be appreciated in disease such as haematological cancers where a substantial  
33   number of abnormal immune cells are present or conversely, where a deficit of specific  
34   immune cell subsets consequently results in increased susceptibility to opportunistic  
35   infections (1–4).

36 During inflammation, this finely balanced sequence must quickly adapt to produce sufficient  
37 immune cells in order to combat injury or infection and replace those dysregulated by the  
38 inflammatory challenge. The cellular kinetics of the inflammatory response encompasses  
39 several cell types including white blood cells, endothelial cells and fibroblasts. Here, we focus  
40 on the cellular kinetics of professional phagocytes, a group of innate myeloid immune cells  
41 (namely monocytes, dendritic cells, macrophages and neutrophils) specialised, but not  
42 limited to, their ability to phagocytose foreign bodies. Tissue macrophages are sentinels that  
43 reside within every tissue in an organism and act as first responders to an infectious agent.  
44 The majority of macrophages are derived from embryonic progenitors (5–8) and play an  
45 important role during tissue development and maintenance (6, 9–14). On the other hand,  
46 neutrophils are recognised for their mechanisms involved in pathogen clearance (e.g. reactive  
47 oxygen species production, degranulation of anti-microbial proteins, neutrophil extracellular  
48 traps (NETs)). Patients diagnosed with neutropenia are often more susceptible to infections  
49 (15, 16) which highlights the need for an adequate production of these cells. Monocytes also  
50 aid in the phagocytosis of pathogens and apoptotic cells, whereas dendritic cells (DC) activate  
51 the adaptive immune response by migrating from the periphery to draining lymph nodes. The  
52 absence of monocytes and DC has been observed in patients bearing mutations in the  
53 transcription factor, interferon regulatory factor 8 (IRF8), as a result, these individuals are  
54 more predisposed to infections (1).

55 Inflammation is necessary to protect an organism from infectious agents, yet an overactive  
56 immune response can result in further tissue damage. This can be observed in chronic  
57 inflammatory diseases such as rheumatoid arthritis where a constant recruitment of  
58 monocytes to the synovial tissue has been observed in humans (17). Therefore, though  
59 inflammation has been historically recognised as a salutary reaction (18), ‘more is more’ is  
60 not often the case. Striking the fine balance of an essential yet limited inflammatory response  
61 may present as a potential therapeutic opportunity. Highlighting the importance of  
62 understanding the kinetics of immune cells in health and disease.

63  
64

## 65 Neutrophil Kinetics

66

67 Neutrophils are an indispensable component of the innate immune system, if not the most  
68 important. Within the circulation, neutrophils constitute the largest proportion of human  
69 circulating leucocytes and estimated to be found at  $\sim 4.2 \times 10^9$  cells per litre of blood although  
70 this can vary with age, ethnicity and sex (19, 20). Neutrophils are often the first white blood  
71 cell recruited to sites of injury, which is facilitated by both the upregulation and expression of  
72 membrane adhesion molecules on the endothelium and neutrophils (21, 22). Increased levels  
73 of neutrophil chemotactic factors such as IL-8 (CXCL8) have been observed early on during  
74 models of human inflammation which aids in the guidance of neutrophils to the site of  
75 inflammation (23, 24). The initial recognition of pathogens by tissue resident macrophages is  
76 also partly responsible for the recruitment of neutrophils (25) although other resident cells

77 can also modulate their infiltration (26). Recent studies in mice and humans have reported a  
78 role for vascular endothelial growth factor  $\alpha$  (VEGF- $\alpha$ ) released from cDC1 in neutrophil  
79 recruitment in cutaneous infections (27).

80 The generation of neutrophils involves a series of maturation steps starting with granulocyte  
81 macrophage progenitors (GMP) in the bone marrow. These cells give rise to pre-neutrophils,  
82 which subsequently develop into immature (band) and mature (segmented) neutrophils  
83 which egress into the circulation (28–30). CXCR4 is a key chemokine receptor involved in the  
84 retention of neutrophils within the bone marrow via interaction with CXCL12, whereas CXCR2  
85 activation promotes the mobilisation of neutrophils from the bone marrow into the blood  
86 (31–33). The importance of the CXCR4 axis in the regulation of neutrophil egression can be  
87 highlighted in Warts, Hypogammaglobulinemia, Immunodeficiency, and Myelokathexis  
88 (WHIM) syndrome patients who primarily suffer from an autosomal, dominant, gain-of-  
89 function mutation in CXCR4 (15, 16). Consequently, these patients suffer from defected  
90 neutrophil egression and thus circulating neutropenia, making them more vulnerable to  
91 infections.

92 Deuterium labelling has been employed to examine human neutrophil development *in vivo*.  
93 Deuterium labelling acts in a non-cytotoxic manner to label dividing cells (34, 35). Using this  
94 approach to monitor neutrophil development, following the last proliferation in the bone  
95 marrow, the mean transit time before neutrophils enter the circulation has been estimated  
96 at 5.8 days (19). Once within the circulation, these cells have an incredibly short half-life of  
97 approximately 19 hours. The short half-life of these cells may reflect their function. Whilst  
98 homeostatic functions have been assigned to neutrophils (36, 37), these cells are renowned  
99 for their defensive mechanisms against invading pathogens such as the production of reactive  
100 oxygen species, antimicrobial peptides and NETosis (38, 39). These mechanisms are not  
101 pathogen specific and can also result in collateral damage to host tissues, therefore it is  
102 thought these cells are likely programmed for a quick cell death in order to prevent excessive  
103 damage.

104 Once in the circulation, neutrophils can either be found within the circulating pool where they  
105 are readily accessible for blood sampling or can be located in a marginating pool. Following a  
106 number of other stimuli including the administration of adrenaline, an intense burst of  
107 exercise, infection or trauma, this marginated pool can be mobilized into the circulating pool  
108 in humans (40, 41), it has been calculated that the marginating pool makes up approximately  
109 50% of the total neutrophil pool (19). Neutrophil transit within tissues refers to how quickly  
110 cells pass through the capillary beds. Within the spleen and bone marrow, it takes  
111 approximately 10 minutes for neutrophils to transit (42, 43). Therefore, the period of time  
112 cells spend within tissues may factor in determining the marginated fraction.

113 Neutrophilia is commonly associated with bacterial infections but can arise from other  
114 stimuli. In human models of local and systemic inflammation, neutrophilia accounts for the  
115 increase in the total white blood cell count (23, 44–46). Of note, left shift refers to the  
116 presence of an increased amount of immature neutrophils within the circulation (47). This  
117 observation has been associated with cancer progression (28) and more recently has been  
118 observed in severe COVID-19 patients which exhibit an immunosuppressive profile (48).

119 Elevated levels of systemic G-CSF during inflammation can lead to both the down-regulation  
120 of CXCR4 (49) and increased levels of CXCR2 ligands (50), which likely leads to an increase in  
121 neutrophil egression. Additionally, an increase in the number of neutrophil progenitors during  
122 inflammation can also contribute the elevation of circulating neutrophils (28), in addition to  
123 neutrophils from the marginating pool. During the resolution of inflammation, neutrophils  
124 are eventually cleared from tissues to restore tissue homeostasis. Neutrophil death can occur  
125 in various ways including apoptosis, necrosis, NETosis and autophagy. Efferocytosis refers to  
126 the phagocytosis of apoptotic cell bodies. The recognition of 'eat me' signals such as  
127 phospholipid phosphatidylserine on apoptotic cells facilitates the recognition by  
128 macrophages and monocyte-derived cells to efferocytose apoptotic bodies (14, 51). Under  
129 steady physiological conditions, senescent neutrophils can also home back to bone marrow  
130 by upregulating CXCR4, where they will also be efferocytosed by resident macrophages (52,  
131 53).

132 These data demonstrate a significant amount of knowledge regarding neutrophils kinetics in  
133 both steady state and inflammation. The next step is to truly understand the kinetic changes  
134 within each compartment of the body i.e. bone marrow, blood and tissue, in addition to the  
135 cues that skew the lifespan of these cells during pathology which may allow for future  
136 targeting to promote an adequate response.

137

## 138 Macrophage Kinetics

139

140 Tissue resident macrophages form a network of cells that reside throughout the organism.  
141 Tissue specific macrophage nomenclature has evolved and is based on anatomical location or  
142 after the scientist who discovered the macrophage population e.g. microglia in the brain,  
143 osteoclasts in the bone or Kupffer cells in the liver and Langerhans cells in the epidermis.

144 The idea that all macrophages arise from monocytes stemmed from studies as early as 1926  
145 demonstrating the ability of monocytes to develop a macrophage phenotype both *in vitro*  
146 (54) and *in vivo* (55). In 1969, Ralph van Furth and colleagues proposed the reticulo-endothelial  
147 system (RES) was too broad a definition and coined the term the 'Mononuclear Phagocyte System' (MPS) including  
148 monocytes and macrophages. Furthermore, Van Furth and colleagues separated macrophages into two clear  
149 categories 'free' or 'fixed' macrophages. When distinguishing the macrophages of the spleen, lymph nodes, and  
150 bone marrow, 'free' macrophages were described as monocyte in origin, while the origin of the 'fixed'  
151 macrophages in these organs remained undetermined (56). This insight into a division of labour of macrophage  
152 ontogeny is reflected at this time with the observation that macrophage development was noted within the  
153 yolk sac prior to bone marrow haematopoiesis (57, 58). These yolk sac macrophages appeared  
154 one day earlier than monocytes in mice and was one of the earliest observations -to the best  
155 of our knowledge- to report macrophage development independent of monocytes (58).  
156 Furthermore, investigations into the kinetics of monocytes and macrophages by Ralph van  
157 Furth and Zan Cohen, using radioactive thymidine, demonstrated low labelling in peritoneal  
158 macrophages compared to blood monocytes (59). Unaware at the time, these data supported  
159 the maintenance of macrophage populations independently of monocytes. More recently,  
160 the use of genetic fate-mapping techniques has confirmed that the majority of tissue-resident

161 macrophages are embryonically derived and maintained without monocyte input (5–8, 60,  
162 61).

163 Within the developing embryo, haematopoiesis occurs in a sequential manner, initially  
164 occurring within the extra-embryonic yolk sac (primitive haematopoiesis) before transferring  
165 to the fetal liver until birth where haematopoiesis is ultimately transferred to the bone  
166 marrow (definitive haematopoiesis) (62). Primitive haematopoiesis begins in the yolk sac,  
167 where erythromyeloid progenitors (EMP) give rise to erythrocytes, macrophages and mast  
168 cells (6, 63). Downstream of the EMP, a pre-macrophage precursor has been identified in mice  
169 which arises in the yolk sac before colonising embryonic tissues around embryonic day 9.5  
170 (E9.5) at the same time as organogenesis (6). These pre-macrophages are subjected to tissue-  
171 specific signals, which help sculpt a tissue-specific resident macrophage phenotype (64).  
172 Recent studies on macrophage development in rodents have been corroborated in humans  
173 where similar findings have been made (65).

174 Following birth, embryonic derived resident macrophages can persist throughout life with  
175 little or no monocyte input depending on the tissue compartment under steady state (8, 61,  
176 66) (**Figure 1**). More recently, a novel fate mapping model utilising the *Ms4a3* gene  
177 demonstrated in a more specific quantitative manner, the monocyte contribution to several  
178 tissue macrophage compartments (66). In tissues such as the brain, skin and liver, monocytes  
179 do not replace the embryonically derived microglia, Langerhans cells and Kupffer cells. Whilst  
180 this has been clearly demonstrated in mice, further clarity is required within the human  
181 setting. Interestingly, Langerhans cells of the skin have been shown to persist of donor origin  
182 - ten years following human hand allograft (67). However, others have found that following  
183 bone marrow transplantation, the majority of Langerhans cells were donor derived within 3  
184 months (68–70). It is important to note chemotherapeutic or other pharmacological regimes  
185 could impact on these studies. The ontogeny of alveolar macrophages in humans has also  
186 been examined in humans where contrasting findings have again been observed (71–73). An  
187 interesting study by Réu and colleagues took advantage of atmospheric <sup>14</sup>C to estimate the  
188 turnover rate of human microglia (74). Increases in atmospheric <sup>14</sup>C in the 1950s due to  
189 nuclear bomb testing resulted in the increased presence of <sup>14</sup>C within the atmosphere and  
190 subsequently DNA of newly formed cells, which in turn could provide insight into the age of a  
191 cell (75). Réu and colleagues demonstrated that human microglia have a life-span of  
192 approximately 4.2 years and renew at a rate of 28% per year (74). Whilst these studies  
193 demonstrate that most macrophages are maintained throughout adulthood, this is not a one-  
194 size-fits-all phenomenon. **Table 1** lists examples of studies where the longevity of macrophage  
195 populations has been examined in both murine models and in the human setting.

196 In the absence of tissue macrophages, a reduced infiltration of granulocytes has been  
197 observed (25), highlighting macrophages as one of the many cell types involved in the  
198 initiation of the immune response. Following the initiation of the immune response, an  
199 interesting phenomenon known as the ‘macrophage disappearance reaction’ occurs, first  
200 described in 1963 (76, 77). This observation has been observed by several groups during  
201 experimental peritonitis, where a reduced recovery of resident macrophages was reported  
202 (78–80). This has also been extended to other tissues, such as the lung where low numbers

203 of alveolar macrophages are recovered following influenza challenge in mice (81) and the liver  
204 where lower number of Kupffer cells are present during inflammation (82, 83). Zhang and  
205 colleagues recently showed that macrophages form clots and adhere to tissues accounting  
206 for the reduced recovery of these cells, which could be reversed by the use of anticoagulants  
207 (80). Following the resolution of inflammation, the recovery of resident macrophage numbers  
208 may occur by proliferation (84), repopulation by monocyte-derived cells (8, 66, 78, 85–87), or  
209 a combination of both (88, 89). Expectedly, exceptions to the macrophage disappearance  
210 paradigm have been observed in T-helper cell type 2 immune response, where tissue resident  
211 macrophages proliferate to combat infection rather than depend on monocyte recruitment  
212 (90).

213

## 214 Monocyte Kinetics

215

216 In Contrast to macrophages, monocytes and DC are derived from bone marrow progenitors.  
217 Initially the monocyte and DC progenitor (MDP) was demonstrated to lack neutrophil  
218 potential yet give rise to monocytes via the common monocyte progenitor (cMoP) (91–93).  
219 Although more recently, the cMoP has been proposed to descend from the granulocyte and  
220 macrophage progenitors (GMP) bypassing the MDP stage in both mice (66) and humans (94).  
221 In this study, the GMP and MDP were suggested to generate monocytes through two  
222 pathways, a GMP → cMoP → monocyte and a MDP → monocyte pathway that lacks a cMoP  
223 intermediate stage (66). Commitment to monocyte development at the cMoP stage is  
224 dependent on the transcription factor IRF8 (95). This is consistent with the observation in  
225 patients bearing mutations in IRF8 who are also deficient of circulating monocytes (1).  
226 Recently, a proliferative CXCR4<sup>hi</sup> CCR2<sup>lo</sup> transitional pre-monocyte population was described  
227 in mice and humans within the bone marrow which eventually downregulates CXCR4 and  
228 upregulates CCR2, resulting in the egression of mature classical monocytes into the circulation  
229 (96–98).

230 The kinetic profiles of circulating monocyte subsets have been examined in mice with the use  
231 of BrdU, where a sequential appearance of labelled classical monocytes then non-classical  
232 monocytes appear in the circulation (8). This is owed to the fact that Ly6C<sup>hi</sup> classical  
233 monocytes convert into Ly6C<sup>lo</sup> non-classical monocytes (8, 66, 93, 99, 100). The half-life of  
234 classical and non-classical monocytes in mice are estimated at 20 hours and 2.2 days,  
235 respectively.

236 Early insights into the kinetics of human monocytes stemmed from studies nearly fifty years  
237 ago with the use of tritiated thymidine where the average monocyte lifespan was estimated  
238 at 4.25 days (101). Deuterated glucose labelling studies proposed a half-life of 2.2 days for  
239 CD14<sup>+ classical</sup> monocytes (102). With regards to monocyte subsets, studies have demonstrated  
240 differences in the kinetic profiles of circulating CD14<sup>+</sup> and CD16<sup>+</sup> monocytes in patients  
241 following hematopoietic stem cell transplantation (103). Using deuterium labelling, a  
242 sequential appearance of monocyte subsets has been observed within the circulation (104,  
243 105). Using mathematical modelling, it was estimated classical monocytes are retained within

244 the bone marrow for approximately 1.6-2 days between the last mitotic division and entry  
245 into the circulation (104, 105) (**Figure 2**). These cells then circulate for approximately 1 day,  
246 whereas non-classical monocytes circulate for a longer period of time (~7.5 days) (105). These  
247 results are akin to those observed in mice (8), rats (106) and macaques (107, 108) most likely  
248 due to a conserved developmental relationship between monocyte subsets.

249 Non-classical monocytes reside within the circulation for a longer period of time possibly due  
250 to their function within the circulation where they are constantly monitoring the endothelium  
251 for damage (109, 110). These cells represent a terminally differentiated monocyte and may  
252 consequently even represent a ‘blood macrophage’ (8). Supplemental components  
253 encourage non-classical monocyte survival include CX<sub>3</sub>CL1 (111) and TNF (112). On the other  
254 hand, classical monocytes are continuously recruited to repopulate tissue mononuclear  
255 phagocyte compartments (60, 66, 103, 113–116) which may explain their shorter circulating  
256 lifespan. Liu *et al.*, demonstrate the rate at which monocytes replaces tissue macrophages in  
257 mice is tissue specific, for example, kidney macrophages are gradually replaced overtime but  
258 to a lesser extent than lung alveolar macrophages or dermal macrophages (66) (**Figure 1**). The  
259 determinants of these rates remain unknown, although, the macrophage niche theory  
260 proposes a niche is filled by the competition between an embryonic macrophage and a  
261 monocyte derived cell (117). Therefore, the differences between tissue microenvironments  
262 most likely dictates the rate of macrophage replacement.

263 In an inflammatory setting, a reduction in the number of circulating monocytes has been  
264 observed in both mice and humans, hours following intravenous endotoxin challenge (44, 96,  
265 105, 118, 119). The lung is a primary location where activated monocytes can marginate to  
266 following challenge (96, 120). Given the narrow diameter of lung capillaries (121), changes in  
267 the morphology and size of monocytes following activation may result in hinderances and  
268 consequently an increased transit time. However, active retention of monocytes within the  
269 lung via CXCR4 retention has also been documented in mice (96). Targeting margination in  
270 the lung may be of clinical relevance as this accumulation of monocytes can promote further  
271 lung injury (120). Following temporary monocytopenia, monocytes can return from various  
272 sources. In mice and humans, the spleen has been implicated as a monocyte reservoir which  
273 are deployed in response to specific inflammatory cues (122, 123). We and others have shown  
274 that bone marrow ‘immature’ classical monocytes are rapidly released into the circulation in  
275 response to bacterial (105) and sterile inflammation (123). More recently, patients with  
276 severe COVID-19 present with immature classical monocytes and neutrophils within the  
277 circulation (48), suggesting this emergency release of monocytes is also apparent in a viral  
278 setting.

279 Intradermal challenges have allowed for the study of immune cell recruitment to the site of  
280 infection in response to various stimuli in humans (23, 124, 125). In response to UV-killed  
281 *Escherichia coli* (*E.coli*), classical monocytes are observed within the skin as early as 8 hours  
282 following challenge (23). This observation is akin to mice, where Ly6C<sup>hi</sup> classical monocytes  
283 are typically the subset recruited (126–128) possibly via a CCR2-dependent manner (98, 122,  
284 127, 129). At later time points, a Ly6C<sup>lo</sup> ‘non-classical’ phenotype is apparent, but it is thought  
285 that this is due to *in situ* conversion rather than a second wave of monocyte recruitment

(126–128, 130, 131). Similarly, in humans, CD16 expression increases over time (23) and may also represent maturation at the site of infection. While it may seem that classical monocytes are the prime effector subset responsible for inflammation and resolution, the use of Nr4a1-deficient mice (132, 133), has highlighted a role of non-classical monocytes in various pathologies including tumour metastasis (134), Alzheimer's disease (135), Experimental Autoimmune Encephalomyelitis (EAE) (136) and vascular homeostasis (110). The role of non-classical monocytes has recently been extensively covered (137). Of note, following the resolution of inflammation, it is thought that tissues return to baseline homeostasis. Whilst this is true at the symptomatic level, immunological processes have been observed to continue in mice where IFNy triggers a second wave of monocyte recruitment creating an immune suppressed environment (138). This may be of importance when considering secondary infections, therefore targeting this second wave of monocytes may be of clinical relevance.

The question arises whether these recruited inflammatory monocytes engraft into the long-lived macrophage pool. In models of peritonitis, monocyte derived cells persist up to 8 weeks, where their phenotype gradually changes into that of resident macrophages (8, 78). Similar observations have been extended to the liver (85, 139–141) and lung (86, 87, 142). It is possible that tissue residence could alter the longevity of monocytes although, in mouse models of experimental autoimmune encephalomyelitis, monocyte-derived cells do not contribute to the resident microglia pool (143) yet contribute to pathology (144), which possibly highlights the microglia as a unique population owed to their unique location within the blood-brain barrier. Whether monocyte-derived cells exhibit the same function as their resident macrophage counterparts is of key importance. In a mouse model, the engraftment of monocyte derived cells into the lung was examined following ten months, the graft cells showed a very similar transcriptome to alveolar macrophages and only exhibited a difference of 330 differentially expressed genes (87). In a separate infection study, the replacement of alveolar macrophages with monocyte-derived cells in response to herpesvirus resulted in protection against house dust mite induced asthma compared with mice without initial exposure to herpesvirus (86). Similar findings have recently been documented, where initial exposure to influenza resulted in subsequent protection from *Streptococcus pneumoniae* due to the recruitment and engraftment of monocytes to the alveolar niche (142). These studies demonstrate, in addition to ontogeny, the context in which monocytes are recruited and the type of stimuli may also shape the function of these cells.

Recent monocyte-like populations have been observed only under pathological conditions, YM1<sup>+</sup> Ly6C<sup>hi</sup> monocytes are greatly expanded within the bone marrow, blood and spleen of mice following intravenous LPS challenge where these cells exhibit immunoregulatory properties and aid in tissue repair (Ikeda *et al.*, 2018). In the case of fibrosis, a segregated nucleus-containing atypical Ly6C<sup>lo</sup> monocyte (SatM) has been documented, although they do not arise from the MDP differentiation route and do not arise from Ly6C<sup>hi</sup> progenitors (Satoh *et al.*, 2017). Inflammation likely skews 'healthy' haematopoiesis, therefore examining the kinetics of these cells under steady conditions will be the initial step and warrants the need to further investigate the development and kinetics of these cells under pathological conditions.

329

330 DC Kinetics

331

332 A common school of thought was - monocytes are the immature precursor cells to  
333 macrophages and DC. However, the identification of the common DC precursor (CDP) that  
334 gave rise exclusively to pDC and cDC, but not monocytes (92, 145, 146), challenged this view  
335 and established a DC dedicated lineage in both rodents and humans. Prior to the generation  
336 of cDC, CDP initially give rise to a cDC precursor (pre-cDC) (145, 147–151) which can be  
337 skewed to pre-cDC1 or pre-cDC2 fate depending on the cues present (95, 149, 150, 152–154).  
338 In humans, pre-cDC can be found within the circulation where they can further mature into  
339 cDC (155–157). On the other hand, mouse pDC are released as mature cells from the bone  
340 marrow and are thought to be derived mostly from lymphoid progenitors (158–160), these  
341 observations are yet to be confirmed in humans.

342 DC are renowned for their ability to stimulate naïve T-cells and subsequently bridge the innate  
343 and adaptive immune response. Numerous DC subsets have been identified, each interacting  
344 with T cells in various ways. DC are found at fewer numbers in comparison to other cell types,  
345 nevertheless a single DC can interact with up to 500 T-cells per hour (161), therefore their low  
346 abundance should not undermine their functional relevance. Though two major cDC subsets  
347 are widely acknowledged (DC1 and DC2), further heterogeneity has recently been identified  
348 within the DC lineage (155, 156, 162–166).

349 BrdU labelling in mice demonstrated a rapid labelling of splenic DC, initially thought to be  
350 attributed to the rapid replenishment from circulating DC precursors (167). However, splenic  
351 DC are also proliferative therefore the labelling is likely to represent a combination of both *in*  
352 *situ* proliferation and blood derivation (168). Parabiosis studies examined the decay of  
353 parabiont-derived DC in the lymphoid and non-lymphoid organs and demonstrated DC are  
354 cleared within 10-14 days (148, 168). Taking into consideration, DC replenishment from blood  
355 precursors, division and cell death, Liu *et al.*, calculated that lymphoid organ cDC are  
356 replenished at a rate of 4,300 cells per hour. This rapid tissue replenishment is supported by  
357 the rapid turnover of blood cDC in macaques, where these cells were labelled prior to  
358 circulating monocytes (108). In humans, donor dermal DC have been identified as early as 18  
359 days following allogeneic haematopoietic cell transplantation and by 56 days were 94% donor  
360 derived (169). Similar studies have also demonstrated that human dermal DC were replaced  
361 by donor origin within 40 days (170). On the contrary, pDC have a much slower turnover in  
362 comparison to cDC in mice (171) and macaques (108), which is possibly owed to a bias  
363 towards cDC production over pDC in the bone marrow (172). Furthermore, the lymphoid  
364 origins of pDC (159, 160) may also account for the differences in kinetics between myeloid  
365 derived cDC.

366 Akin to monocytes, a reduced number of circulating cDC and pDC have been reported during  
367 inflammation in both mice (173–175) and humans (176–181). The fate of these DC remains  
368 unknown although DC death is thought to be a factor (175). An elegant study by Pasquevich  
369 and colleagues demonstrated monopoiesis is favoured over DC production following bacterial  
370 infection in mice (182). Following TLR4 mediated inflammation, these mice had reduced

371 numbers of CDP but elevated numbers of cMoP. It is possible the body increases the  
372 availability of monocytes to combat infection at the expense of DC, however this leads to an  
373 immunosuppressive state. Interestingly, the rescue of DC from cell death (175) or increasing  
374 DC production via FLT3 ligand (183) reduced the inflammatory induced immunosuppression  
375 and improved DC survival. Similarly, correlations between circulating DC count and survival  
376 from secondary infections in sepsis patients have been documented (176, 177). Further  
377 exploration into DC kinetics in this setting could present a potential therapeutic target.  
378 However, given the diversity of dendritic cell subsets, it is first necessary to understand the  
379 foundational biology of these cells and their relationship to one another.

## 380 Conclusion

381

382 Phagocytes play a crucial role in facilitating the immune response, yet little is known about  
383 the tightly regulated processes governing the generation, maturation and disappearance of  
384 these cells, which allow them to fulfil their functions. Whilst macrophages are considered as  
385 a self-maintaining population it is clear this is not the case for all tissues. The question arises  
386 – what determines the longevity of macrophages? Why are the rates of monocyte  
387 replacement variable between tissues? And consequently, what does this mean functionally?  
388 Similarly, given the recent expansion of DC diversity in humans, our knowledge regarding the  
389 relationship of the cells to one another, in addition to their individual functions remains  
390 limited. This review summarises both our current understanding and highlights the gaps in  
391 our knowledge of one of the foundational aspects of phagocyte biology. By establishing the  
392 kinetics and turnover of these cells in addition to the regulatory mechanisms behind, this may  
393 allow for therapies to fine tune the immune response.

## 394 Figure and Table Legends

395

396 **Figure 1. Tissue macrophage kinetics with age.** Illustrative diagram demonstrating the  
397 relative and differential rates of blood monocyte contribution to tissue macrophage  
398 populations. Adapted from Liu *et al.*, 2019

399 **Figure 2. Overview of monocyte kinetics in health and inflammation.** Under steady  
400 physiological conditions, classical monocytes arise from cMoP and reside within the bone  
401 marrow for approximately 1.6 days before being released into the circulation. Once within  
402 the circulation, these cells mature into intermediate and then non-classical monocytes, which  
403 circulate for 4 and 7 days, respectively. During systemic inflammation, classical monocytes  
404 are rapidly released into the circulation. Following local injury, classical monocytes are initially  
405 recruited later followed an intermediate monocyte phenotype, although the origin of the cells  
406 are unknown (dashed lines). HSC, hematopoietic stem cell; cMoP, common monocyte  
407 progenitor.

408 Table 1. **Longevity of phagocytes.** Summary of longevity of phagocyte populations in mouse  
409 and humans. Life-spans and half-live have been stated where available. TBC, to be confirmed.

410

## 411 References

- 412 1. Hambleton, S., S. Salem, J. Bustamante, V. Bigley, S. Boisson-Dupuis, J. Azevedo, A. Fortin, M.  
413 Haniffa, L. Ceron-Gutierrez, C. M. Bacon, G. Menon, C. Trouillet, D. McDonald, P. Carey, F. Ginhoux,  
414 L. Alsina, T. J. Zumwalt, X.-F. Kong, D. Kumararatne, K. Butler, M. Hubeau, J. Feinberg, S. Al-Muhsen,  
415 A. Cant, L. Abel, D. Chaussabel, R. Doffinger, E. Talesnik, A. Grumach, A. Duarte, K. Abarca, D.  
416 Moraes-Vasconcelos, D. Burk, A. Berghuis, F. Geissmann, M. Collin, J.-L. Casanova, and P. Gros. 2011.  
417 *IRF8 Mutations and Human Dendritic-Cell Immunodeficiency*. *N. Engl. J. Med.* 365: 127–138.
- 418 2. Buckley, R. H. 2004. The multiple causes of human SCID. *J. Clin. Invest.* 114: 1409–1411.
- 419 3. Kumrah, R., P. Vignesh, P. Patra, A. Singh, G. Anjani, P. Saini, M. Sharma, A. Kaur, and A. Rawat.  
420 2020. Genetics of severe combined immunodeficiency. *Genes Dis.* 7: 52–61.
- 421 4. Salzer, E., E. Santos-Valente, S. Klaver, S. A. Ban, W. Emminger, N. K. Prengemann, W. Garncarz, L.  
422 Müllauer, R. Kain, H. Boztug, A. Heitger, K. Arbeiter, F. Eitelberger, M. G. Seidel, W. Holter, A. Pollak,  
423 W. F. Pickl, E. Förster-Waldl, and K. Boztug. 2013. B-cell deficiency and severe autoimmunity caused  
424 by deficiency of protein kinase C δ. *Blood* 121: 3112–3116.
- 425 5. Ginhoux, F., M. Greter, M. Leboeuf, S. Nandi, P. See, S. Gokhan, M. F. Mehler, S. J. Conway, L. G.  
426 Ng, E. R. Stanley, I. M. Samokhvalov, and M. Merad. 2010. Fate mapping analysis reveals that adult  
427 microglia derive from primitive macrophages. *Science* 330: 841–5.
- 428 6. Mass, E., I. Ballesteros, M. Farlik, F. Halbritter, P. Günther, L. Crozet, C. E. Jacome-Galarza, K.  
429 Händler, J. Klughammer, Y. Kobayashi, E. Gomez-Perdiguero, J. L. Schultze, M. Beyer, C. Bock, and F.  
430 Geissmann. 2016. Specification of tissue-resident macrophages during organogenesis. *Science* 353:  
431 aaf4238–aaf4238.
- 432 7. Schulz, C., E. G. Perdiguer, L. Chorro, H. Szabo-Rogers, N. Cagnard, K. Kierdorf, M. Prinz, B. Wu, S.  
433 E. W. Jacobsen, J. W. Pollard, J. Frampton, K. J. Liu, and F. Geissmann. 2012. A Lineage of Myeloid  
434 Cells Independent of Myb and Hematopoietic Stem Cells. *Science (80-. ).* 336: 86–90.
- 435 8. Yona, S., K.-W. Kim, Y. Wolf, A. Mildner, D. Varol, M. Breker, D. Strauss-Ayali, S. Viukov, M.  
436 Guilliams, A. Misharin, D. A. Hume, H. Perlman, B. Malissen, E. Zelzer, and S. Jung. 2013. Fate  
437 mapping reveals origins and dynamics of monocytes and tissue macrophages under homeostasis.  
438 *Immunity* 38: 79–91.
- 439 9. Paolicelli, R. C., G. Bolasco, F. Pagani, L. Maggi, M. Scianni, P. Panzanelli, M. Giustetto, T. A.  
440 Ferreira, E. Guiducci, L. Dumas, D. Ragazzino, and C. T. Gross. 2011. Synaptic pruning by microglia is  
441 necessary for normal brain development. *Science* 333: 1456–8.
- 442 10. Dai, X.-M., G. R. Ryan, A. J. Hapel, M. G. Dominguez, R. G. Russell, S. Kapp, V. Sylvestre, and E. R.  
443 Stanley. 2002. Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in  
444 osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies,  
445 and reproductive defects. *Blood* 99: 111–20.
- 446 11. Ryan, G. R., X. M. Dai, M. G. Dominguez, W. Tong, F. Chuan, O. Chisholm, R. G. Russell, J. W.  
447 Pollard, and E. R. Stanley. 2001. Rescue of the colony-stimulating factor 1 (CSF-1)-nullizygous mouse  
448 (*Csf1<sup>op</sup>/Csf1<sup>op</sup>*) phenotype with a CSF-1 transgene and identification of sites of local CSF-1  
449 synthesis. *Blood* 98: 74–84.
- 450 12. Kohyama, M., W. Ise, B. T. Edelson, P. R. Wilker, K. Hildner, C. Mejia, W. a Frazier, T. L. Murphy,  
451 and K. M. Murphy. 2009. Role for Spi-C in the development of red pulp macrophages and splenic  
452 iron homeostasis. *Nature* 457: 318–21.
- 453 13. van de Laar, L., W. Saelens, S. De Prijck, L. Martens, C. L. Scott, G. Van Isterdael, E. Hoffmann, R.  
454 Beyaert, Y. Saeys, B. N. Lambrecht, and M. Guilliams. 2016. Yolk Sac Macrophages, Fetal Liver, and

- 455 Adult Monocytes Can Colonize an Empty Niche and Develop into Functional Tissue-Resident  
456 Macrophages. *Immunity* 44: 755–768.
- 457 14. Roberts, A. W., B. L. Lee, J. Deguine, S. John, M. J. Shlomchik, and G. M. Barton. 2017. Tissue-  
458 Resident Macrophages Are Locally Programmed for Silent Clearance of Apoptotic Cells. *Immunity* 47:  
459 913–927.e6.
- 460 15. Balabanian, K., B. Lagane, J. L. Pablos, L. Laurent, T. Planchenault, O. Verola, C. Lebbe, D. Kerob,  
461 A. Dupuy, O. Hermine, J. F. Nicolas, V. Latger-Cannard, D. Bensoussan, P. Bordigoni, F. Baleux, F. Le  
462 Deist, J. L. Virelizier, F. Arenzana-Seisdedos, and F. Bachelerie. 2005. WHIM syndromes with different  
463 genetic anomalies are accounted for by impaired CXCR4 desensitization to CXCL12. *Blood* 105: 2449–  
464 2457.
- 465 16. Hernandez, P. A., R. J. Gorlin, J. N. Lukens, S. Taniuchi, J. Bohinjec, F. Francois, M. E. Klotman, and  
466 G. A. Diaz. 2003. Mutations in the chemokine receptor gene CXCR4 are associated with WHIM  
467 syndrome, a combined immunodeficiency disease. *Nat. Genet.* 34: 70–74.
- 468 17. Thurlings, R. M., C. A. Wijbrandts, R. J. Bennink, S. E. Dohmen, C. Voermans, D. Wouters, E. S.  
469 Izmailova, D. M. Gerlag, B. L. F. van Eck-Smit, and P. P. Tak. 2009. Monocyte Scintigraphy in  
470 Rheumatoid Arthritis: The Dynamics of Monocyte Migration in Immune-Mediated Inflammatory  
471 Disease. *PLoS One* 4: e7865.
- 472 18. Hunter, J. 1794. *A treatise on the blood, inflammation, and gun-shot wounds Title*,. J. Richardson  
473 for G. Nicol, London.
- 474 19. Lahoz-Beneytez, J., M. Elemans, Y. Zhang, R. Ahmed, A. Salam, M. Block, C. Niederalt, B. Asquith,  
475 and D. Macallan. 2016. Human neutrophil kinetics: Modeling of stable isotope labeling data supports  
476 short blood neutrophil half-lives. *Blood* 127: 3431–3438.
- 477 20. Hsieh, M. M., J. E. Everhart, D. D. Byrd-Holt, J. F. Tisdale, and G. P. Rodgers. 2007. Prevalence of  
478 neutropenia in the U.S. population: Age, sex, smoking status, and ethnic differences. *Ann. Intern.*  
479 *Med.* 146: 486–492.
- 480 21. Bargatze, R. F., S. Kurk, E. C. Butcher, and M. A. Jutila. 1994. Neutrophils Roll on Adherent  
481 Neutrophils Bound to Cytokine-induced Endothelial Cells via L-Selectin on the Rolling Cells. *J. Exp.*  
482 *Med.* 180: 1785–1792.
- 483 22. Kolaczkowska, E., and P. Kubes. 2013. Neutrophil recruitment and function in health and  
484 inflammation. *Nat. Rev. Immunol.* 13: 159–175.
- 485 23. Motwani, M. P., J. D. Flint, R. P. De Maeyer, J. N. Fullerton, A. M. Smith, D. J. Marks, and D. W.  
486 Gilroy. 2016. Novel translational model of resolving inflammation triggered by UV-killed *E. coli*. *J.*  
487 *Pathol. Clin. Res.* 2: 154–165.
- 488 24. de Oliveira, S., C. C. Reyes-Aldasoro, S. Candel, S. A. Renshaw, V. Mulero, and Â. Calado. 2013.  
489 Cxcl8 (IL-8) Mediates Neutrophil Recruitment and Behavior in the Zebrafish Inflammatory Response.  
490 *J. Immunol.* 190: 4349–4359.
- 491 25. Cailhier, J. F., M. Partolina, S. Vuthoori, S. Wu, K. Ko, S. Watson, J. Savill, J. Hughes, and R. A.  
492 Lang. 2005. Conditional macrophage ablation demonstrates that resident macrophages initiate acute  
493 peritoneal inflammation. *J. Immunol.* 174: 2336–42.
- 494 26. Kim, N. D., and A. D. Luster. 2015. The role of tissue resident cells in neutrophil recruitment.  
495 *Trends Immunol.* 36: 547–555.
- 496 27. Janelia, B., A. A. Patel, M. C. Lau, C. C. Goh, R. Msallam, W. T. Kong, M. Fehlings, S. Hubert, J. Lum,  
497 Y. Simoni, B. Malleret, F. Zolezzi, J. Chen, M. Poidinger, A. T. Satpathy, C. Briseno, C. Wohn, B.

- 498 Malissen, K. M. Murphy, A. A. Maini, L. Vanhoutte, M. Guilliams, E. Vial, L. Hennequin, E. Newell, L.  
499 G. Ng, P. Musette, S. Yona, F. Hacini-Rachinel, and F. Ginhoux. 2019. A Subset of Type I Conventional  
500 Dendritic Cells Controls Cutaneous Bacterial Infections through VEGF $\alpha$ -Mediated Recruitment of  
501 Neutrophils. *Immunity* 50: 1069-1083.e8.
- 502 28. Evrard, M., I. W. H. Kwok, S. Z. Chong, K. W. W. Teng, E. Becht, J. Chen, J. L. Sieow, H. L. Penny, G.  
503 C. Ching, S. Devi, J. M. Adrover, J. L. Y. Li, K. H. Liong, L. Tan, Z. Poon, S. Foo, J. W. Chua, I.-H. Su, K.  
504 Balabanian, F. Bachelerie, S. K. Biswas, A. Larbi, W. Y. K. Hwang, V. Madan, H. P. Koeffler, S. C. Wong,  
505 E. W. Newell, A. Hidalgo, F. Ginhoux, and L. G. Ng. 2018. Developmental Analysis of Bone Marrow  
506 Neutrophils Reveals Populations Specialized in Expansion, Trafficking, and Effector Functions.  
507 *Immunity* 48: 364-379.e8.
- 508 29. Kwok, I., E. Becht, Y. Xia, M. Ng, Y. C. Teh, L. Tan, M. Evrard, J. L. Y. Li, H. T. N. Tran, Y. Tan, D. Liu,  
509 A. Mishra, K. H. Liong, K. Leong, Y. Zhang, A. Olsson, C. K. Mantri, P. Shyamsunder, Z. Liu, C. Piot, C.-  
510 A. Dutertre, H. Cheng, S. Bari, N. Ang, S. K. Biswas, H. P. Koeffler, H. L. Tey, A. Larbi, I.-H. Su, B. Lee, A.  
511 St. John, J. K. Y. Chan, W. Y. K. Hwang, J. Chen, N. Salomonis, S. Z. Chong, H. L. Grimes, B. Liu, A.  
512 Hidalgo, E. W. Newell, T. Cheng, F. Ginhoux, and L. G. Ng. 2020. Combinatorial Single-Cell Analyses of  
513 Granulocyte-Monocyte Progenitor Heterogeneity Reveals an Early Uni-potent Neutrophil Progenitor.  
514 *Immunity* 0.
- 515 30. Dinh, H. Q., T. Eggert, M. A. Meyer, Y. P. Zhu, C. E. Olingy, R. Llewellyn, R. Wu, and C. C. Hedrick.  
516 2020. Coexpression of CD71 and CD117 Identifies an Early Unipotent Neutrophil Progenitor  
517 Population in Human Bone Marrow. *Immunity* 53: 319-334.e6.
- 518 31. Eash, K. J., A. M. Greenbaum, P. K. Gopalan, and D. C. Link. 2010. CXCR2 and CXCR4  
519 antagonistically regulate neutrophil trafficking from murine bone marrow. *J. Clin. Invest.* 120: 2423–  
520 2431.
- 521 32. Suratt, B. T., J. M. Petty, S. K. Young, K. C. Malcolm, J. G. Lieber, J. A. Nick, J. A. Gonzalo, P. M.  
522 Henson, and G. S. Worthen. 2004. Role of the CXCR4/SDF-1 chemokine axis in circulating neutrophil  
523 homeostasis. *Blood* 104: 565–571.
- 524 33. Mei, J., Y. Liu, N. Dai, C. Hoffmann, K. M. Hudock, P. Zhang, S. H. Guttentag, J. K. Kolls, P. M.  
525 Oliver, F. D. Bushman, and G. S. Worthen. 2012. Cxcr2 and Cxcl5 regulate the IL-17/G-CSF axis and  
526 neutrophil homeostasis in mice. *J. Clin. Invest.* 122: 974–986.
- 527 34. Busch, R., R. a Neese, M. Awada, G. M. Hayes, and M. K. Hellerstein. 2007. Measurement of cell  
528 proliferation by heavy water labeling. *Nat. Protoc.* 2: 3045–3057.
- 529 35. Macallan, D. C., B. Asquith, Y. Zhang, C. de Lara, H. Ghattas, J. Defoiche, and P. C. L. Beverley.  
530 2009. Measurement of proliferation and disappearance of rapid turnover cell populations in human  
531 studies using deuterium-labeled glucose. *Nat. Protoc.* 4: 1313–27.
- 532 36. Puga, I., M. Cols, C. M. Barra, B. He, L. Cassis, M. Gentile, L. Comerma, A. Chorny, M. Shan, W. Xu,  
533 G. Magri, D. M. Knowles, W. Tam, A. Chiu, J. B. Bussel, S. Serrano, J. A. Lorente, B. Bellosillo, J.  
534 Lloreta, N. Juanpere, F. Alameda, T. Baró, C. D. De Heredia, N. Torán, A. Català, M. Torrebadell, C.  
535 Fortuny, V. Cusí, C. Carreras, G. A. Diaz, J. M. Blander, C. M. Farber, G. Silvestri, C. Cunningham-  
536 Rundles, M. Calvillo, C. Dufour, L. D. Notarangelo, V. Lougaris, A. Plebani, J. L. Casanova, S. C. Ganal,  
537 A. Diefenbach, J. I. Aróstegui, M. Juan, J. Yagüe, N. Mahlaoui, J. Donadieu, K. Chen, and A. Cerutti.  
538 2012. B cell-helper neutrophils stimulate the diversification and production of immunoglobulin in  
539 the marginal zone of the spleen. *Nat. Immunol.* 13: 170–180.
- 540 37. Casanova-Acebes, M., C. Pitaval, L. A. Weiss, C. Nombela-Arrieta, R. Chèvre, N. A-González, Y.  
541 Kunisaki, D. Zhang, N. van Rooijen, L. E. Silberstein, C. Weber, T. Nagasawa, P. S. Frenette, A.  
542 Castrillo, and A. Hidalgo. 2013. Rhythmic Modulation of the Hematopoietic Niche through Neutrophil  
543 Clearance. *Cell* 153: 1025–1035.

- 544 38. Lehman, H. K., and B. H. Segal. 2020. The role of neutrophils in host defense and disease. *J.*  
545 *Allergy Clin. Immunol.* 145: 1535–1544.
- 546 39. Segal, A. W. 2005. How neutrophils kill microbes. *Annu. Rev. Immunol.* 23: 197–223.
- 547 40. Athens, J. W., O. P. Haab, S. O. Raab, A. M. Mauer, H. Ashenbrucker, G. E. Cartwright, and M. M.  
548 Wintrobe. 1961. Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools  
549 and the granulocyte turnover rate in normal subjects. *J. Clin. Invest.* 40: 989–95.
- 550 41. Neves, P. R. D. S., T. R. D. S. Tenório, T. A. Lins, M. T. C. Muniz, T. C. Pithon-Curi, J. P. Botero, and  
551 W. L. Do Prado. 2015. Acute effects of high- and low-intensity exercise bouts on leukocyte counts. *J.*  
552 *Exerc. Sci. Fit.* 13: 24–28.
- 553 42. Peters, A. M., S. H. Saverymuttu, A. Keshavarzian, R. N. Bell, and J. P. Lavender. 1985. Splenic  
554 pooling of granulocytes. *Clin. Sci.* 68: 283–289.
- 555 43. Usov, W. Y., C. Aktolun, M. J. Myers, F. Jamar, and A. M. Peters. 1995. Granulocyte margination  
556 in bone marrow: Comparison with margination in the spleen and liver. *Scand. J. Clin. Lab. Invest.* 55:  
557 87–96.
- 558 44. Tak, T., R. van Groenendaal, P. Pickkers, and L. Koenderman. 2017. Monocyte Subsets Are  
559 Differentially Lost from the Circulation during Acute Inflammation Induced by Human Experimental  
560 Endotoxemia. *J. Innate Immun.* 9: 464–474.
- 561 45. Fullerton, J. N., E. Segre, R. P. H. De Maeyer, A. A. N. Maini, and D. W. Gilroy. 2016. Intravenous  
562 Endotoxin Challenge in Healthy Humans: An Experimental Platform to Investigate and Modulate  
563 Systemic Inflammation. *J. Vis. Exp.* 1–8.
- 564 46. Basran, A., M. Jabeen, L. Bingle, C. A. Stokes, D. H. Dockrell, M. K. B. Whyte, S. R. Walmsley, K. R.  
565 Higgins, S. N. Vogel, H. L. Wilson, L. R. Prince, E. C. Prestwich, R. A. Sabroe, L. C. Parker, and I. Sabroe.  
566 2013. Roles of neutrophils in the regulation of the extent of human inflammation through delivery of  
567 IL-1 and clearance of chemokines. *J. Leukoc. Biol.* 93: 7–19.
- 568 47. Honda, T., T. Uehara, G. Matsumoto, S. Arai, and M. Sugano. 2016. Neutrophil left shift and white  
569 blood cell count as markers of bacterial infection. *Clin. Chim. Acta* 457: 46–53.
- 570 48. Silvin, A., N. Chapuis, G. Dunsmore, A. G. Goubet, A. Dubuisson, L. Derosa, C. Almire, C. Hénon, O.  
571 Kosmider, N. Droin, P. Rameau, C. Catelain, A. Alfaro, C. Dussiau, C. Friedrich, E. Sourdeau, N. Marin,  
572 T. A. Szwebel, D. Cantin, L. Mouthon, D. Borderie, M. Deloger, D. Bredel, S. Mouraud, D. Drubay, M.  
573 Andrieu, A. S. Lhonneur, V. Saada, A. Stoclin, C. Willekens, F. Pommeret, F. Grisicelli, L. G. Ng, Z.  
574 Zhang, P. Bost, I. Amit, F. Barlesi, A. Marabelle, F. Pène, B. Gachot, F. André, L. Zitvogel, F. Ginhoux,  
575 M. Fontenay, and E. Solary. 2020. Elevated Calprotectin and Abnormal Myeloid Cell Subsets  
576 Discriminate Severe from Mild COVID-19. *Cell* 182: 1401-1418.e18.
- 577 49. Kim, H. K., M. De La Luz Sierra, C. K. Williams, A. V. Gulino, and G. Tosato. 2006. G-CSF down-  
578 regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. *Blood*  
579 108: 812–820.
- 580 50. Köhler, A., K. De Filippo, M. Hasenberg, C. Van Den Brandt, E. Nye, M. P. Hosking, T. E. Lane, L.  
581 Männ, R. M. Ransohoff, A. E. Hauser, O. Winter, B. Schraven, H. Geiger, N. Hogg, and M. Gunzer.  
582 2011. G-CSF-mediated thrombopoietin release triggers neutrophil motility and mobilization from  
583 bone marrow via induction of Cxcr2 ligands. *Blood* 117: 4349–4357.
- 584 51. Gordy, C., H. Pua, G. D. Sempowski, and Y. W. He. 2011. Regulation of steady-state neutrophil  
585 homeostasis by macrophages. *Blood* 117: 618–629.
- 586 52. Furze, R. C., and S. M. Rankin. 2008. The role of the bone marrow in neutrophil clearance under

- 587 homeostatic conditions in the mouse. *FASEB J.* 22: 3111–3119.
- 588 53. Martin, C., P. C. E. Burdon, G. Bridger, J. C. Gutierrez-Ramos, T. J. Williams, and S. M. Rankin.  
589 2003. Chemokines acting via CXCR2 and CXCR4 control the release of neutrophils from the bone  
590 marrow and their return following senescence. *Immunity* 19: 583–593.
- 591 54. Carrel, A., and A. H. Ebeling. 1926. The fundamental properties of the fibroblast and the  
592 macrophage. *J. Exp. Med.* 44: 285–306.
- 593 55. Ebert, R. H., and H. W. Florey. 1939. The Extravascular Development of the Monocyte Observed  
594 In vivo. *Br. J. Exp. Pathol.* 20: 342.
- 595 56. van Furth, R., Z. A. Cohn, J. G. Hirsch, J. H. Humphrey, W. G. Spector, and H. L. Langevoort. 1972.  
596 The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their  
597 precursor cells. *Bull. World Health Organ.* 46: 845–852.
- 598 57. Cline, M. J., and M. A. Moore. 1972. Embryonic origin of the mouse macrophage. *Blood* 39: 842–  
599 9.
- 600 58. Takahashi, K. 1989. Differentiation , Maturation , and Proliferation Macrophages in the Mouse  
601 Yolk Sac : of and Ultrastructural Study. *J. Leukoc. Biol.* 96: 87–96.
- 602 59. van Furth, R., and Z. A. Cohn. 1968. The origin and kinetics of mononuclear phagocytes. *J. Exp.*  
603 *Med.* 128: 415–35.
- 604 60. Epelman, S., K. J. Lavine, A. E. Beaudin, D. K. Sojka, J. A. Carrero, B. Calderon, T. Brij, E. L.  
605 Gautier, S. Ivanov, A. T. Satpathy, J. D. Schilling, R. Schwendener, I. Sergin, B. Razani, E. C. Forsberg,  
606 W. M. Yokoyama, E. R. Unanue, M. Colonna, G. J. Randolph, and D. L. Mann. 2014. Embryonic and  
607 adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady  
608 state and during inflammation. *Immunity* 40: 91–104.
- 609 61. Hashimoto, D., A. Chow, C. Noizat, P. Teo, M. B. Beasley, M. Leboeuf, C. D. Becker, P. See, J. Price,  
610 D. Lucas, M. Greter, A. Mortha, S. W. Boyer, E. C. Forsberg, M. Tanaka, N. van Rooijen, A. García-  
611 Sastre, E. R. Stanley, F. Ginhoux, P. S. Frenette, and M. Merad. 2013. Tissue-Resident Macrophages  
612 Self-Maintain Locally throughout Adult Life with Minimal Contribution from Circulating Monocytes.  
*Immunity* 38: 792–804.
- 614 62. Ginhoux, F., and S. Jung. 2014. Monocytes and macrophages: developmental pathways and  
615 tissue homeostasis. *Nat. Rev. Immunol.* 14: 392–404.
- 616 63. Palis, J., S. Robertson, M. Kennedy, C. Wall, and G. Keller. 1999. Development of erythroid and  
617 myeloid progenitors in the yolk sac and embryo proper of the mouse. *Development* 126: 5073–5084.
- 618 64. Lavin, Y., D. Winter, R. Blecher-Gonen, E. David, H. Keren-Shaul, M. Merad, S. Jung, and I. Amit.  
619 2014. Tissue-resident macrophage enhancer landscapes are shaped by the local microenvironment.  
620 *Cell* 159: 1312–1326.
- 621 65. Bian, Z., Y. Gong, T. Huang, C. Z. W. Lee, L. Bian, Z. Bai, H. Shi, Y. Zeng, C. Liu, J. He, J. Zhou, X. Li,  
622 Z. Li, Y. Ni, C. Ma, L. Cui, R. Zhang, J. K. Y. Chan, L. G. Ng, Y. Lan, F. Ginhoux, and B. Liu. 2020.  
623 Deciphering human macrophage development at single-cell resolution. *Nature* 1–6.
- 624 66. Liu, Z., Y. Gu, S. Chakarov, C. Blieriot, I. Kwok, X. Chen, A. Shin, W. Huang, R. J. Dress, C.-A.  
625 Dutertre, A. Schlitzer, J. Chen, L. G. Ng, H. Wang, Z. Liu, B. Su, and F. Ginhoux. 2019. Fate Mapping via  
626 Ms4a3-Expression History Traces Monocyte-Derived Cells. *Cell* 178: 1509-1525.e19.
- 627 67. Kanitakis, J., E. Morelon, P. Petruzzo, L. Badet, and J. M. Dubernard. 2011. Self-renewal capacity  
628 of human epidermal Langerhans cells: Observations made on a composite tissue allograft. *Exp.*  
629 *Dermatol.* 20: 145–146.

- 630 68. Mielcarek, M., A. Y. Kirkorian, R. C. Hackman, J. Price, B. E. Storer, B. L. Wood, M. Leboeuf, M.  
631 Bogunovic, R. Storb, Y. Inamoto, M. E. Flowers, P. J. Martin, M. Collin, and M. Merad. 2014.  
632 Langerhans cell homeostasis and turnover after nonmyeloablative and myeloablative allogeneic  
633 hematopoietic cell transplantation. *Transplantation* 98: 563–568.
- 634 69. Collin, M. P., D. N. J. Hart, G. H. Jackson, G. Cook, J. Cavet, S. Mackinnon, P. G. Middleton, and A.  
635 M. Dickinson. 2006. The fate of human Langerhans cells in hematopoietic stem cell transplantation.  
636 *J. Exp. Med.* 203: 27–33.
- 637 70. Volc-Platzer, B., G. Stingl, K. Wolff, W. Hinterberg, and W. Schnedl. 1984. Cytogenetic  
638 Identification of Allogeneic Epidermal Langerhans Cells in a Bone-Marrow–Graft Recipient. *N. Engl. J.  
639 Med.* 310: 1123–1124.
- 640 71. Nayak, D. K., F. Zhou, M. Xu, J. Huang, M. Tsuji, R. Hachem, and T. Mohanakumar. 2016. Long-  
641 Term Persistence of Donor Alveolar Macrophages in Human Lung Transplant Recipients That  
642 Influences Donor-Specific Immune Responses. *Am. J. Transplant.* 16: 2300–2311.
- 643 72. Byrne, A. J., J. E. Powell, B. J. O’Sullivan, P. P. Ogger, A. Hoffland, J. Cook, K. L. Bonner, R. J.  
644 Hewitt, S. Wolf, P. Ghai, S. A. Walker, S. W. Lukowski, P. L. Molyneaux, S. Saglani, D. C. Chambers, T.  
645 M. Maher, and C. M. Lloyd. 2020. Dynamics of human monocytes and airway macrophages during  
646 healthy aging and after transplant. *J. Exp. Med.* 217.
- 647 73. Thomas, E. D., R. E. Ramberg, G. E. Sale, R. S. Sparkes, and D. W. Golde. 1976. Direct evidence for  
648 a bone marrow origin of the alveolar macrophage in man. *Science (80-)*. 192: 1016–1018.
- 649 74. Réu, P., A. Khosravi, S. Bernard, J. E. Mold, M. Salehpour, K. Alkass, S. Perl, J. Tisdale, G. Possnert,  
650 H. Druid, and J. Frisén. 2017. The Lifespan and Turnover of Microglia in the Human Brain. *Cell Rep.*  
651 20: 779–784.
- 652 75. Spalding, K. L., R. D. Bhardwaj, B. A. Buchholz, H. Druid, and J. Frisén. 2005. Retrospective birth  
653 dating of cells in humans. *Cell* 122: 133–143.
- 654 76. Barth, M. W., J. A. Hendrzak, M. J. Melnicoff, and P. S. Morahan. 1995. Review of the  
655 macrophage disappearance reaction. *J. Leukoc. Biol.* 57: 361–7.
- 656 77. Nelson, D. S. 1963. Reaction to antigens *in vivo* of the peritoneal macrophages of guinea-pigs  
657 with delayed type hypersensitivity. Effects of anticoagulants and other drugs. *Lancet* 282: 175–176.
- 658 78. Newson, J., M. Stables, E. Karra, F. Arce-Vargas, S. Quezada, M. Motwani, M. Mack, S. Yona, T.  
659 Audzevich, and D. W. Gilroy. 2014. Resolution of acute inflammation bridges the gap between innate  
660 and adaptive immunity. *Blood* 124: 1748–64.
- 661 79. Davies, L. C., M. Rosas, S. J. Jenkins, C.-T. Liao, M. J. Scurr, F. Brombacher, D. J. Fraser, J. E. Allen,  
662 S. a Jones, and P. R. Taylor. 2013. Distinct bone marrow-derived and tissue-resident macrophage  
663 lineages proliferate at key stages during inflammation. *Nat. Commun.* 4: 1886.
- 664 80. Zhang, N., R. S. Czepielewski, N. N. Jarjour, E. C. Erlich, E. Esaulova, B. T. Saunders, S. P. Grover, A.  
665 C. Cleuren, G. J. Broze, B. T. Edelson, N. Mackman, B. H. Zinselmeyer, and G. J. Randolph. 2019.  
666 Expression of factor V by resident macrophages boosts host defense in the peritoneal cavity. *J. Exp.  
667 Med.* 216: 1291–1300.
- 668 81. Lauder, S. N., P. R. Taylor, S. R. Clark, R. L. Evans, J. P. Hindley, K. Smart, H. Leach, E. J. Kidd, K. J.  
669 Broadley, S. A. Jones, M. P. Wise, A. J. Godkin, V. O’Donnell, and A. M. Gallimore. 2011. Paracetamol  
670 reduces influenza-induced immunopathology in a mouse model of infection without compromising  
671 virus clearance or the generation of protective immunity. *Thorax* 66: 368–74.
- 672 82. Zigmond, E., S. Samia-Grinberg, M. Pasmanik-Chor, E. Brazowski, O. Shibolet, Z. Halpern, and C.

- 673 Varol. 2014. Infiltrating Monocyte-Derived Macrophages and Resident Kupffer Cells Display Different  
674 Ontogeny and Functions in Acute Liver Injury. *J. Immunol.* 193: 344–353.
- 675 83. Ramachandran, P., A. Pellicoro, M. a Vernon, L. Boulter, R. L. Aucott, A. Ali, S. N. Hartland, V. K.  
676 Snowdon, A. Cappon, T. T. Gordon-Walker, M. J. Williams, D. R. Dunbar, J. R. Manning, N. van  
677 Rooijen, J. a Fallowfield, S. J. Forbes, and J. P. Iredale. 2012. Differential Ly-6C expression identifies  
678 the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis.  
679 *Proc. Natl. Acad. Sci. U. S. A.* 109: E3186-95.
- 680 84. Davies, L. C., M. Rosas, P. J. Smith, D. J. Fraser, S. A. Jones, and P. R. Taylor. 2011. A quantifiable  
681 proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute  
682 inflammation. *Eur. J. Immunol.* 41: 2155–2164.
- 683 85. Blériot, C., T. Dupuis, G. Jouvion, G. Eberl, O. Disson, and M. Lecuit. 2015. Liver-Resident  
684 Macrophage Necroptosis Orchestrates Type 1 Microbicidal Inflammation and Type-2-Mediated  
685 Tissue Repair during Bacterial Infection. *Immunity* 42: 145–158.
- 686 86. Machiels, B., M. Dourcy, X. Xiao, J. Javaux, C. Mesnil, C. Sabatel, D. Desmecht, F. Lallemand, P.  
687 Martinive, H. Hammad, M. Guilliams, B. Dewals, A. Vanderplasschen, B. N. Lambrecht, F. Bureau, and  
688 L. Gillet. 2017. A gammaherpesvirus provides protection against allergic asthma by inducing the  
689 replacement of resident alveolar macrophages with regulatory monocytes. *Nat. Immunol.* 18: 1310–  
690 1320.
- 691 87. Misharin, A. V, L. Morales-Nebreda, P. A. Reyman, C. M. Cuda, J. M. Walter, A. C. McQuattie-  
692 Pimentel, C.-I. Chen, K. R. Anekalla, N. Joshi, K. J. N. Williams, H. Abdala-Valencia, T. J. Yacoub, M.  
693 Chi, S. Chiu, F. J. Gonzalez-Gonzalez, K. Gates, A. P. Lam, T. T. Nicholson, P. J. Homan, S. Soberanes, S.  
694 Dominguez, V. K. Morgan, R. Saber, A. Shaffer, M. Hinchcliff, S. A. Marshall, A. Bharat, S. Berdnikovs,  
695 S. M. Bhorade, E. T. Bartom, R. I. Morimoto, W. E. Balch, J. I. Sznajder, N. S. Chandel, G. M. Mutlu, M.  
696 Jain, C. J. Gottardi, B. D. Singer, K. M. Ridge, N. Bagheri, A. Shilatifard, G. R. S. Budinger, and H.  
697 Perlman. 2017. Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung  
698 over the life span. *J. Exp. Med.* 214: 2387–2404.
- 699 88. Scott, C. L., F. Zheng, P. De Baetselier, L. Martens, Y. Saeys, S. De Prijck, S. Lippens, C. Abels, S.  
700 Schoonooghe, G. Raes, N. Devoogdt, B. N. Lambrecht, A. Beschin, and M. Guilliams. 2016. Bone  
701 marrow-derived monocytes give rise to self-renewing and fully differentiated Kupffer cells. *Nat.  
702 Commun.* 7: 10321.
- 703 89. Bonnardel, J., W. T'Jonck, D. Gaublomme, R. Browaeys, C. L. Scott, L. Martens, B. Vanneste, S. De  
704 Prijck, S. A. Nedospasov, A. Kremer, E. Van Hamme, P. Borghgraef, W. Toussaint, P. De Bleser, I.  
705 Mannaerts, A. Beschin, L. A. van Grunsven, B. N. Lambrecht, T. Taghon, S. Lippens, D. Elewaut, Y.  
706 Saeys, and M. Guilliams. 2019. Stellate Cells, Hepatocytes, and Endothelial Cells Imprint the Kupffer  
707 Cell Identity on Monocytes Colonizing the Liver Macrophage Niche. *Immunity* 51: 638-654.e9.
- 708 90. Jenkins, S. J., D. Ruckerl, P. C. Cook, L. H. Jones, F. D. Finkelman, N. van Rooijen, A. S. MacDonald,  
709 and J. E. Allen. 2011. Local Macrophage Proliferation, Rather than Recruitment from the Blood, Is a  
710 Signature of TH2 Inflammation. *Science (80-. ).* 332: 1284–1288.
- 711 91. Bajaña, S., K. Roach, S. Turner, J. Paul, and S. Kovats. 2012. IRF4 Promotes Cutaneous Dendritic  
712 Cell Migration to Lymph Nodes during Homeostasis and Inflammation. *J. Immunol.* 189: 3368–3377.
- 713 92. Lee, J., G. Breton, T. Y. K. Oliveira, Y. J. Zhou, A. Aljoufi, S. Puhr, M. J. Cameron, R.-P. Sékaly, M. C.  
714 Nussenzweig, and K. Liu. 2015. Restricted dendritic cell and monocyte progenitors in human cord  
715 blood and bone marrow. *J. Exp. Med.* 212: 385–399.
- 716 93. Hettinger, J., D. M. Richards, J. Hansson, M. M. Barra, A.-C. C. Joschko, J. Krijgsveld, and M.  
717 Feuerer. 2013. Origin of monocytes and macrophages in a committed progenitor. *Nat. Immunol.* 14:

- 718 821–30.
- 719 94. Kawamura, S., N. Onai, F. Miya, T. Sato, T. Tsunoda, K. Kurabayashi, S. Yotsumoto, S. Kuroda, K.  
720 Takenaka, K. Akashi, and T. Ohteki. 2017. Identification of a Human Clonogenic Progenitor with Strict  
721 Monocyte Differentiation Potential: A Counterpart of Mouse cMoPs. *Immunity* 46: 835–848.e4.
- 722 95. Sichien, D., C. L. Scott, L. Martens, M. Vanderkerken, S. Van Gassen, M. Plantinga, T. Joeris, S. De  
723 Prijck, L. Vanhoutte, M. Vanheerswyngels, G. Van Isterdael, W. Toussaint, F. B. Madeira, K. Vergote,  
724 W. W. Agace, B. E. Clausen, H. Hammad, M. Dalod, Y. Saeys, B. N. Lambrecht, and M. Guilliams.  
725 2016. IRF8 Transcription Factor Controls Survival and Function of Terminally Differentiated  
726 Conventional and Plasmacytoid Dendritic Cells, Respectively. *Immunity* 45: 626–640.
- 727 96. Chong, S. Z., M. Evrard, S. Devi, J. Chen, J. Y. Lim, P. See, Y. Zhang, J. M. Adrover, B. Lee, L. Tan, J.  
728 L. Y. Li, K. H. Liong, C. Phua, A. Balachander, A. Boey, D. Liebl, S. M. Tan, J. K. Y. Chan, K. Balabanian, J.  
729 E. Harris, M. Bianchini, C. Weber, J. Duchene, J. Lum, M. Poidinger, Q. Chen, L. Rénia, C.-I. Wang, A.  
730 Larbi, G. J. Randolph, W. Weninger, M. R. Looney, M. F. Krummel, S. K. Biswas, F. Ginhoux, A.  
731 Hidalgo, F. Bachelerie, and L. G. Ng. 2016. CXCR4 identifies transitional bone marrow premonocytes  
732 that replenish the mature monocyte pool for peripheral responses. *J. Exp. Med.* 213: 2293–2314.
- 733 97. Jung, H., D. S. Mithal, J. E. Park, and R. J. Miller. 2015. Localized CCR2 activation in the bone  
734 marrow niche mobilizes monocytes by desensitizing CXCR4. *PLoS One* 10: e0128387.
- 735 98. Serbina, N. V., and E. G. Pamer. 2006. Monocyte emigration from bone marrow during bacterial  
736 infection requires signals mediated by chemokine receptor CCR2. *Nat. Immunol.* 7: 311–317.
- 737 99. Mildner, A., J. Schönheit, A. Giladi, E. David, D. Lara-Astiaso, E. Lorenzo-Vivas, F. Paul, L. Chappell-  
738 Maor, J. Priller, A. Leutz, I. Amit, and S. Jung. 2017. Genomic Characterization of Murine Monocytes  
739 Reveals C/EBP $\beta$  Transcription Factor Dependence of Ly6C – Cells. *Immunity* 46: 849–862.e7.
- 740 100. Varol, C., L. Landsman, D. K. Fogg, L. Greenshtein, B. Gildor, R. Margalit, V. Kalchenko, F.  
741 Geissmann, and S. Jung. 2007. Monocytes give rise to mucosal, but not splenic, conventional  
742 dendritic cells. *J. Exp. Med.* 204: 171–80.
- 743 101. Whitelaw, D. M. 1972. Observations on human monocyte kinetics after pulse labelling. *Cell  
744 Prolif.* 5: 311–317.
- 745 102. Mohri, H., a S. Perelson, K. Tung, R. M. Ribeiro, B. Ramratnam, M. Markowitz, R. Kost, A.  
746 Hurley, L. Weinberger, D. Cesar, M. K. Hellerstein, and D. D. Ho. 2001. Increased turnover of T  
747 lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. *J. Exp. Med.* 194: 1277–  
748 1287.
- 749 103. McGovern, N., A. Schlitzer, M. Gunawan, L. Jardine, A. Shin, E. Poyner, K. Green, R. Dickinson,  
750 X.-N. Wang, D. Low, K. Best, S. Covins, P. Milne, S. Pagan, K. Aljefri, M. Windebank, D. Miranda-  
751 Saavedra, D. M. Saavedra, A. Larbi, P. S. Wasan, K. Duan, M. Poidinger, V. Bigley, F. Ginhoux, M.  
752 Collin, and M. Haniffa. 2014. Human dermal CD14 $^{+}$  cells are a transient population of monocyte-  
753 derived macrophages. *Immunity* 41: 465–77.
- 754 104. Tak, T., J. Drylewicz, L. Conemans, R. J. de Boer, L. Koenderman, J. A. M. Borghans, and K.  
755 Tesselaar. 2017. Circulatory and maturation kinetics of human monocyte subsets in vivo. *Blood* 130:  
756 1474–1477.
- 757 105. Patel, A. A., Y. Zhang, J. N. Fullerton, L. Boelen, A. Rongvaux, A. A. Maini, V. Bigley, R. A. Flavell,  
758 D. W. Gilroy, B. Asquith, D. Macallan, and S. Yona. 2017. The fate and lifespan of human monocyte  
759 subsets in steady state and systemic inflammation. *J. Exp. Med.* 214: 1913–1923.
- 760 106. Yrlid, U., C. D. Jenkins, and G. G. MacPherson. 2006. Relationships between distinct blood  
761 monocyte subsets and migrating intestinal lymph dendritic cells in vivo under steady-state

- 762 conditions. *J. Immunol.* 176: 4155–62.
- 763 107. Burdo, T. H., C. Soulas, K. Orzechowski, J. Button, A. Krishnan, C. Sugimoto, X. Alvarez, M. J.  
764 Kuroda, and K. C. Williams. 2010. Increased monocyte turnover from bone marrow correlates with  
765 severity of SIV encephalitis and CD163 levels in plasma. *PLoS Pathog.* 6: e1000842.
- 766 108. Sugimoto, C., A. Hasegawa, Y. Saito, Y. Fukuyo, K. B. Chiu, Y. Cai, M. W. Breed, K. Mori, C. J. Roy,  
767 A. A. Lackner, W.-K. Kim, E. S. Didier, and M. J. Kuroda. 2015. Differentiation Kinetics of Blood  
768 Monocytes and Dendritic Cells in Macaques: Insights to Understanding Human Myeloid Cell  
769 Development. *J. Immunol.* 195: 1774–1781.
- 770 109. Auffray, C., D. Fogg, M. Garfa, G. Elain, O. Join-Lambert, S. Kayal, S. Sarnacki, A. Cumano, G.  
771 Lauvau, and F. Geissmann. 2007. Monitoring of blood vessels and tissues by a population of  
772 monocytes with patrolling behavior. *Science* 317: 666–70.
- 773 110. Carlin, L. M., E. G. Stamatiades, C. Auffray, R. N. Hanna, L. Glover, G. Vizcay-Barrena, C. C.  
774 Hedrick, H. T. Cook, S. Diebold, and F. Geissmann. 2013. Nr4a1-dependent Ly6Clow monocytes  
775 monitor endothelial cells and orchestrate their disposal. *Cell* 153: 362–375.
- 776 111. Landsman, L., L. Bar-On, A. Zernecke, K.-W. Kim, R. Krauthgamer, E. Shagdarsuren, S. a Lira, I. L.  
777 Weissman, C. Weber, and S. Jung. 2009. CX3CR1 is required for monocyte homeostasis and  
778 atherogenesis by promoting cell survival. *Blood* 113: 963–72.
- 779 112. Wolf, Y., A. Shemer, M. Polonsky, M. Gross, A. Mildner, S. Yona, E. David, K. W. Kim, T.  
780 Goldmann, I. Amit, M. Heikenwalder, S. Nedospasov, M. Prinz, N. Friedman, and S. Jung. 2017.  
781 Autonomous TNF is critical for in vivo monocyte survival in steady state and inflammation. *J. Exp.  
782 Med.* .
- 783 113. Bain, C. C., A. Bravo-Blas, C. L. Scott, E. Gomez Perdiguero, F. Geissmann, S. Henri, B. Malissen,  
784 L. C. Osborne, D. Artis, and A. M. Mowat. 2014. Constant replenishment from circulating monocytes  
785 maintains the macrophage pool in the intestine of adult mice. *Nat. Immunol.* 15: 929–937.
- 786 114. Jakubzick, C., F. Tacke, J. Llodra, N. van Rooijen, and G. J. Randolph. 2006. Modulation of  
787 Dendritic Cell Trafficking to and from the Airways. *J. Immunol.* 176: 3578–3584.
- 788 115. Kim, K.-W., J. W. Williams, Y.-T. Wang, S. Ivanov, S. Gilfillan, M. Colonna, H. W. Virgin, E. L.  
789 Gautier, and G. J. Randolph. 2016. MHC II + resident peritoneal and pleural macrophages rely on  
790 IRF4 for development from circulating monocytes. *J. Exp. Med.* 213: 1951–1959.
- 791 116. Mossadegh-Keller, N., R. Gentek, G. Gimenez, S. Bigot, S. Mailfert, and M. H. Sieweke. 2017.  
792 Developmental origin and maintenance of distinct testicular macrophage populations. *J. Exp. Med.*  
793 214: 2829–2841.
- 794 117. Guilliams, M., and C. L. Scott. 2017. Does niche competition determine the origin of tissue-  
795 resident macrophages? *Nat. Rev. Immunol.* 17: 451–460.
- 796 118. Thaler, B., P. J. Hohensinner, K. A. Krychtiuk, P. Matzneller, L. Koller, M. Brekalo, G. Maurer, K.  
797 Huber, M. Zeitlinger, B. Jilma, J. Wojta, and W. S. Speidl. 2016. Differential in vivo activation of  
798 monocyte subsets during low-grade inflammation through experimental endotoxemia in humans.  
799 *Sci. Rep.* 6: 30162.
- 800 119. Shi, C., T. Jia, S. Mendez-Ferrer, T. M. Hohl, N. V. Serbina, L. Lipuma, I. Leiner, M. O. Li, P. S.  
801 Frenette, and E. G. Pamer. 2011. Bone Marrow Mesenchymal Stem and Progenitor Cells Induce  
802 Monocyte Emigration in Response to Circulating Toll-like Receptor Ligands. *Immunity* 34: 590–601.
- 803 120. O'Dea, K. P., M. R. Wilson, J. O. Dokpesi, K. Wakabayashi, L. Tatton, N. van Rooijen, and M.  
804 Takata. 2009. Mobilization and margination of bone marrow Gr-1high monocytes during subclinical

- 805 endotoxemia predisposes the lungs toward acute injury. *J. Immunol.* 182: 1155–66.
- 806 121. Doerschuk, C. M., N. Beyers, H. O. Coxson, B. Wiggs, and J. C. Hogg. 1993. Comparison of  
807 neutrophil and capillary diameters and their relation to neutrophil sequestration in the lung. *J. Appl.*  
808 *Physiol.* 74: 3040–5.
- 809 122. Swirski, F. K., M. Nahrendorf, M. Etzrodt, M. Wildgruber, V. Cortez-Retamozo, P. Panizzi, J.-L.  
810 Figueiredo, R. H. Kohler, A. Chudnovskiy, P. Waterman, E. Aikawa, T. R. Mempel, P. Libby, R.  
811 Weissleder, and M. J. Pittet. 2009. Identification of Splenic Reservoir Monocytes and Their  
812 Deployment to Inflammatory Sites. *Science* (80-. ). 325: 612–616.
- 813 123. van der Laan, A. M., E. N. ter Horst, R. Delewi, M. P. V Begieneman, P. A. J. Krijnen, A. Hirsch, M.  
814 Lavaei, M. Nahrendorf, A. J. Horrevoets, H. W. M. Niessen, and J. J. Piek. 2014. Monocyte subset  
815 accumulation in the human heart following acute myocardial infarction and the role of the spleen as  
816 monocyte reservoir. *Eur. Heart J.* 35: 376–385.
- 817 124. Jenner, W., M. Motwani, K. Veighey, J. Newson, T. Audzevich, A. Nicolaou, S. Murphy, R.  
818 MacAllister, and D. W. Gilroy. 2014. Characterisation of leukocytes in a human skin blister model of  
819 acute inflammation and resolution. *PLoS One* 9: e89375.
- 820 125. Eguíluz-Gracia, I., A. Bosco, R. Dollner, G. R. Melum, M. H. Lexberg, A. C. Jones, S. A.  
821 Dheyaaldeen, P. G. Holt, E. S. Bækkevold, and F. L. Jahnsen. 2016. Rapid recruitment of CD14 +  
822 monocytes in experimentally induced allergic rhinitis in human subjects. *J. Allergy Clin. Immunol.*  
823 137: 1872-1881.e12.
- 824 126. Hilgendorf, I., L. M. S. Gerhardt, T. C. Tan, C. Winter, T. A. W. Holderried, B. G. Chousterman, Y.  
825 Iwamoto, R. Liao, A. Zirlik, M. Scherer-Crosbie, C. C. Hedrick, P. Libby, M. Nahrendorf, R. Weissleder,  
826 and F. K. Swirski. 2014. Ly-6Chi monocytes depend on Nr4a1 to balance both inflammatory and  
827 reparative phases in the infarcted myocardium. *Circ. Res.* 114: 1611–22.
- 828 127. Zigmond, E., C. Varol, J. Farache, E. Elmaliah, A. T. Satpathy, G. Friedlander, M. Mack, N. Shpigel,  
829 I. G. Boneca, K. M. Murphy, G. Shakhar, Z. Halpern, and S. Jung. 2012. Ly6Chi Monocytes in the  
830 Inflamed Colon Give Rise to Proinflammatory Effector Cells and Migratory Antigen-Presenting Cells.  
831 *Immunity* 37: 1076–1090.
- 832 128. Dal-Secco, D., J. Wang, Z. Zeng, E. Kolaczkowska, C. H. Y. Wong, B. Petri, R. M. Ransohoff, I. F.  
833 Charo, C. N. Jenne, and P. Kubes. 2015. A dynamic spectrum of monocytes arising from the in situ  
834 reprogramming of CCR2 + monocytes at a site of sterile injury. *J. Exp. Med.* 212: 447–456.
- 835 129. Tsou, C. L., W. Peters, Y. Si, S. Slaymaker, A. M. Aslanian, S. P. Weisberg, M. Mack, and I. F.  
836 Charo. 2007. Critical roles for CCR2 and MCP-3 in monocyte mobilization from bone marrow and  
837 recruitment to inflammatory sites. *J. Clin. Invest.* 117: 902–909.
- 838 130. Arnold, L., A. Henry, F. Poron, Y. Baba-Amer, N. Van Rooijen, A. Plonquet, R. K. Gherardi, and B.  
839 Chazaud. 2007. Inflammatory monocytes recruited after skeletal muscle injury switch into  
840 antiinflammatory macrophages to support myogenesis. *J. Exp. Med.* 204: 1057–1069.
- 841 131. Avraham-David, I., S. Yona, M. Grunewald, L. Landsman, C. Cochran, J. S. Silvestre, H. Mizrahi,  
842 M. Faroja, D. Strauss-Ayali, M. Mack, S. Jung, and E. Keshet. 2013. On-site education of VEGF-  
843 recruited monocytes improves their performance as angiogenic and arteriogenic accessory cells. *J.*  
844 *Exp. Med.* 210: 2611–2625.
- 845 132. Hanna, R. N., L. M. Carlin, H. G. Hubbeling, D. Nackiewicz, A. M. Green, J. A. Punt, F. Geissmann,  
846 and C. C. Hedrick. 2011. The transcription factor NR4A1 (Nur77) controls bone marrow  
847 differentiation and the survival of Ly6C- monocytes. *Nat. Immunol.* 12: 778–785.
- 848 133. Thomas, G. D., R. N. Hanna, N. T. Vasudevan, A. A. Hamers, C. E. Romanoski, S. McArdle, K. D.

- 849 Ross, A. Blatchley, D. Yoakum, B. A. Hamilton, Z. Mikulski, M. K. Jain, C. K. Glass, and C. C. Hedrick.  
850 2016. Deleting an Nr4a1 Super-Enhancer Subdomain Ablates Ly6Clow Monocytes while Preserving  
851 Macrophage Gene Function. *Immunity* 45: 975–987.
- 852 134. Hanna, R. N., C. Cekic, D. Sag, R. Tacke, G. D. Thomas, H. Nowyhed, E. Herrley, S. Mcardle, R.  
853 Wu, and E. Peluso. 2015. Patrolling monocytes control tumor metastasis to the lung. *Science* (80-. ).  
854 1–9.
- 855 135. Michaud, J.-P., M.-A. Bellavance, P. Préfontaine, and S. Rivest. 2013. Real-Time In Vivo Imaging  
856 Reveals the Ability of Monocytes to Clear Vascular Amyloid Beta. *Cell Rep.* 5: 646–653.
- 857 136. Shaked, I., R. N. Hanna, H. Shaked, G. Chodaczek, H. N. Nowyhed, G. Tweet, R. Tacke, A. B.  
858 Basat, Z. Mikulski, S. Togher, J. Miller, A. Blatchley, S. Salek-Ardakani, M. Darvas, M. U. Kaikkonen, G.  
859 D. Thomas, S. Lai-Wing-Sun, A. Rezk, A. Bar-Or, C. K. Glass, H. Bandukwala, and C. C. Hedrick. 2015.  
860 Transcription factor Nr4a1 couples sympathetic and inflammatory cues in CNS-recruited  
861 macrophages to limit neuroinflammation. *Nat. Immunol.* 16: 1228–1234.
- 862 137. Babu Narasimhan, P., P. Marcovecchio, A. A. Hamers, and C. C. Hedrick. 2019. Nonclassical  
863 Monocytes in Health and Disease. .
- 864 138. Newson, J., M. P. Motwani, A. C. Kendall, A. Nicolaou, G. G. Muccioli, M. Alhouayek, M. Bennett,  
865 R. Van De Merwe, S. James, R. P. H. De Maeyer, and D. W. Gilroy. 2017. Inflammatory Resolution  
866 Triggers a Prolonged Phase of Immune Suppression through COX-1/mPGES-1-Derived Prostaglandin  
867 E2. *Cell Rep.* 20: 3162–3175.
- 868 139. Seidman, J. S., T. D. Troutman, M. Sakai, A. Gola, N. J. Spann, H. Bennett, C. M. Bruni, Z. Ouyang,  
869 R. Z. Li, X. Sun, B. C. T. Vu, M. P. Pasillas, K. M. Ego, D. Gosselin, V. M. Link, L. W. Chong, R. M. Evans,  
870 B. M. Thompson, J. G. McDonald, M. Hosseini, J. L. Witztum, R. N. Germain, and C. K. Glass. 2020.  
871 Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in  
872 Nonalcoholic Steatohepatitis. *Immunity* 52: 1057–1074.e7.
- 873 140. Remmerie, A., L. Martens, T. Thoné, A. Castoldi, R. Seurinck, B. Pavie, J. Roels, B. Vanneste, S.  
874 De Prijck, M. Vanhockerhout, M. Binte Abdul Latib, L. Devisscher, A. Hoorens, J. Bonnardel, N.  
875 Vandamme, A. Kremer, P. Borghgraef, H. Van Vlierberghe, S. Lippens, E. Pearce, Y. Saeys, and C. L.  
876 Scott. 2020. Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from  
877 Kupffer Cells in the Fatty Liver. *Immunity* 53: 641–657.e14.
- 878 141. Tran, S., I. Baba, L. Poupel, S. Dussaud, M. Moreau, A. Gélineau, G. Marcellin, E. Magréau-Davy,  
879 M. Ouhachi, P. Lesnik, A. Boissonnas, W. Le Goff, B. E. Clausen, L. Yvan-Charvet, F. Sennlaub, T. Huby,  
880 and E. L. Gautier. 2020. Impaired Kupffer Cell Self-Renewal Alters the Liver Response to Lipid  
881 Overload during Non-alcoholic Steatohepatitis. *Immunity* 53: 627–640.e5.
- 882 142. Aegeerter, H., J. Kulikauskaitė, S. Crotta, H. Patel, G. Kelly, E. M. Hessel, M. Mack, S. Beinke, and  
883 A. Wack. 2020. Influenza-induced monocyte-derived alveolar macrophages confer prolonged  
884 antibacterial protection. *Nat. Immunol.* 21: 145–157.
- 885 143. Ajami, B., J. L. Bennett, C. Krieger, K. M. McNagny, and F. M. V Rossi. 2011. Infiltrating  
886 monocytes trigger EAE progression, but do not contribute to the resident microglia pool. *Nat.*  
887 *Neurosci.* 14: 1142–1150.
- 888 144. Giladi, A., L. K. Wagner, H. Li, D. Dörr, C. Medaglia, F. Paul, A. Shemer, S. Jung, S. Yona, M. Mack,  
889 A. Leutz, I. Amit, and A. Mildner. 2020. Cxcl10 + monocytes define a pathogenic subset in the central  
890 nervous system during autoimmune neuroinflammation. *Nat. Immunol.* 21: 525–534.
- 891 145. Liu, K., G. D. Victora, T. A. Schwickert, P. Guermonprez, M. M. Meredith, K. Yao, F.-F. F.-F. Chu,  
892 G. J. Randolph, A. Y. Rudensky, and M. Nussenzweig. 2009. In Vivo Analysis of Dendritic Cell

- 893 Development and Homeostasis. *Science* 324: 392–397.
- 894 146. Onai, N., A. Obata-Onai, M. a Schmid, T. Ohteki, D. Jarrossay, and M. G. Manz. 2007.  
895 Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell  
896 progenitors in mouse bone marrow. *Nat. Immunol.* 8: 1207–16.
- 897 147. Donnenberg, V. S., P. J. O'Connell, A. J. Logar, A. Zeevi, A. W. Thomson, and A. D. Donnenberg.  
898 2001. Rare-event analysis of circulating human dendritic cell subsets and their presumptive mouse  
899 counterparts. *Transplantation* 72: 1946–1951.
- 900 148. Ginhoux, F., K. Liu, J. Helft, M. Bogunovic, M. Greter, D. Hashimoto, J. Price, N. Yin, J. Bromberg,  
901 S. A. Lira, E. R. Stanley, M. Nussenzweig, and M. Merad. 2009. The origin and development of  
902 nonlymphoid tissue CD103 + DCs. *J. Exp. Med.* 206: 3115–3130.
- 903 149. Naik, S. H., P. Sathe, H.-Y. Park, D. Metcalf, A. I. Proietto, A. Dakic, S. Carotta, M. O'Keefe, M.  
904 Bahlo, A. Papenfuss, J.-Y. Kwak, L. Wu, and K. Shortman. 2007. Development of plasmacytoid and  
905 conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo. *Nat.*  
906 *Immunol.* 8: 1217–26.
- 907 150. Naik, S. H., D. Metcalf, A. van Nieuwenhuijze, I. Wicks, L. Wu, M. O'Keefe, and K. Shortman.  
908 2006. Intrasplenic steady-state dendritic cell precursors that are distinct from monocytes. *Nat.*  
909 *Immunol.* 7: 663–71.
- 910 151. O'Keefe, M., H. Hochrein, D. Vremec, B. Scott, P. Hertzog, L. Tatarczuch, and K. Shortman.  
911 2003. Dendritic cell precursor populations of mouse blood: Identification of the murine homologues  
912 of human blood plasmacytoid pre-DC2 and CD11c+ DC1 precursors. *Blood* 101: 1453–1459.
- 913 152. Cabeza-Cabrero, M., J. van Blijswijk, S. Wienert, D. Heim, R. P. Jenkins, P. Chakravarty, N.  
914 Rogers, B. Frederico, S. Acton, E. Beerling, J. van Rheenen, H. Clevers, B. U. Schraml, M. Bajénoff, M.  
915 Gerner, R. N. Germain, E. Sahai, F. Klauschen, and C. Reis e Sousa. 2019. Tissue clonality of dendritic  
916 cell subsets and emergency DCpoiesis revealed by multicolor fate mapping of DC progenitors. *Sci.*  
917 *Immunol.* 4: eaaw1941.
- 918 153. Grajales-Reyes, G. E., A. Iwata, J. Albring, X. Wu, R. Tussiwand, W. KC, N. M. Kretzer, C. G.  
919 Briseño, V. Durai, P. Bagadia, M. Haldar, J. Schönheit, F. Rosenbauer, T. L. Murphy, and K. M.  
920 Murphy. 2015. Batf3 maintains autoactivation of Irf8 for commitment of a CD8α+ conventional DC  
921 clonogenic progenitor. *Nat. Immunol.* 16: 708–717.
- 922 154. Schlitzer, A., V. Sivakamasundari, J. Chen, H. R. Bin Sumatoh, J. Schreuder, J. Lum, B. Malleret, S.  
923 Zhang, A. Larbi, F. Zolezzi, L. Renia, M. Poidinger, S. Naik, E. W. Newell, P. Robson, and F. Ginhoux.  
924 2015. Identification of cDC1- and cDC2-committed DC progenitors reveals early lineage priming at  
925 the common DC progenitor stage in the bone marrow. *Nat Immunol* 16: 718–728.
- 926 155. See, P., C.-A. Dutertre, J. Chen, P. Günther, N. McGovern, S. E. Irac, M. Gunawan, M. Beyer, K.  
927 Händler, K. Duan, H. R. Bin Sumatoh, N. Ruffin, M. Jouve, E. Gea-Mallorquí, R. C. M. Hennekam, T.  
928 Lim, C. C. Yip, M. Wen, B. Malleret, I. Low, N. B. Shadan, C. F. S. Fen, A. Tay, J. Lum, F. Zolezzi, A.  
929 Larbi, M. Poidinger, J. K. Y. Chan, Q. Chen, L. Rénia, M. Haniffa, P. Benaroch, A. Schlitzer, J. L.  
930 Schultze, E. W. Newell, and F. Ginhoux. 2017. Mapping the human DC lineage through the  
931 integration of high-dimensional techniques. *Science* 356: eaag3009.
- 932 156. Villani, A.-C., R. Satija, G. Reynolds, S. Sarkizova, K. Shekhar, J. Fletcher, M. Griesbeck, A. Butler,  
933 S. Zheng, S. Lazo, L. Jardine, D. Dixon, E. Stephenson, E. Nilsson, I. Grundberg, D. McDonald, A. Filby,  
934 W. Li, P. L. De Jager, O. Rozenblatt-Rosen, A. A. Lane, M. Haniffa, A. Regev, and N. Hacohen. 2017.  
935 Single-cell RNA-seq reveals new types of human blood dendritic cells, monocytes, and progenitors.  
936 *Science* (80- ). 356: eaah4573.

- 937 157. Breton, G., J. Lee, Y. J. Zhou, J. J. Schreiber, T. Keler, S. Puhr, N. Anandasabapathy, S.  
938 Schlesinger, M. Caskey, K. Liu, and M. C. Nussenzweig. 2015. Circulating precursors of human CD1c+  
939 and CD141+ dendritic cells. *J. Exp. Med.* 212: 401–13.
- 940 158. Onai, N., K. Kurabayashi, M. Hosoi-Amaike, N. Toyama-Sorimachi, K. Matsushima, K. Inaba, and  
941 T. Ohteki. 2013. A Clonogenic Progenitor with Prominent Plasmacytoid Dendritic Cell Developmental  
942 Potential. *Immunity* 38: 943–957.
- 943 159. Rodrigues, P. F., L. Alberti-Servera, A. Eremin, G. E. Grajales-Reyes, R. Ivanek, and R. Tussiwand.  
944 2018. Distinct progenitor lineages contribute to the heterogeneity of plasmacytoid dendritic cells.  
945 *Nat. Immunol.* 19: 711–722.
- 946 160. Dress, R. J., C. A. Dutertre, A. Giladi, A. Schlitzer, I. Low, N. B. Shadan, A. Tay, J. Lum, M. F. B. M.  
947 Kairi, Y. Y. Hwang, E. Becht, Y. Cheng, M. Chevrier, A. Larbi, E. W. Newell, I. Amit, J. Chen, and F.  
948 Ginhoux. 2019. Plasmacytoid dendritic cells develop from Ly6D+ lymphoid progenitors distinct from  
949 the myeloid lineage. *Nat. Immunol.* 20: 852–864.
- 950 161. Bousso, P., and E. Robey. 2003. Dynamics of CD8+ T cell priming by dendritic cells in intact  
951 lymph nodes. *Nat. Immunol.* 4: 579–585.
- 952 162. Dutertre, C.-A., E. Becht, S. E. Irac, A. Khalilnezhad, V. Narang, S. Khalilnezhad, P. Y. Ng, L. L. van  
953 den Hoogen, J. Y. Leong, B. Lee, M. Chevrier, X. M. Zhang, P. J. A. Yong, G. Koh, J. Lum, S. W.  
954 Howland, E. Mok, J. Chen, A. Larbi, H. K. K. Tan, T. K. H. Lim, P. Karagianni, A. G. Tzioufas, B. Malleret,  
955 J. Brody, S. Albani, J. van Roon, T. Radstake, E. W. Newell, and F. Ginhoux. 2019. Single-Cell Analysis  
956 of Human Mononuclear Phagocytes Reveals Subset-Defining Markers and Identifies Circulating  
957 Inflammatory Dendritic Cells. *Immunity* 51: 573–589.e8.
- 958 163. Bourdely, P., G. Anselmi, K. Vaivode, R. N. Ramos, Y. Missolo-Koussou, S. Hidalgo, J. Tosselo, N.  
959 Nuñez, W. Richer, A. Vincent-Salomon, A. Saxena, K. Wood, A. Lladser, E. Piaggio, J. Helft, and P.  
960 Guermonprez. 2020. Transcriptional and Functional Analysis of CD1c+ Human Dendritic Cells  
961 Identifies a CD163+ Subset Priming CD8+CD103+ T Cells. *Immunity* 0.
- 962 164. Cytlak, U., A. Resteu, S. Pagan, K. Green, P. Milne, S. Maisuria, D. McDonald, G. Hulme, A. Filby,  
963 B. Carpenter, R. Queen, S. Hambleton, R. Hague, H. Lango Allen, J. E. D. Thaventhiran, G. Doody, M.  
964 Collin, and V. Bigley. 2020. Differential IRF8 Transcription Factor Requirement Defines Two Pathways  
965 of Dendritic Cell Development in Humans. *Immunity* 53: 353–370.e8.
- 966 165. Bosteels, C., K. Neyt, M. Vanheerswynghels, H. Hammad, M. Guilliams, B. N. Lambrecht, M. J.  
967 Van Helden, D. Sichien, N. Debeuf, S. De Prijck, V. Bosteels, N. Vandamme, L. Martens, Y. Saeys, E.  
968 Louagie, M. Lesage, D. L. Williams, S.-C. Tang, J. U. Mayer, F. Ronchese, and C. L. Scott. 2020.  
969 Inflammatory Type 2 cDCs Acquire Features of cDC1s and Macrophages to Orchestrate Immunity to  
970 Respiratory Virus Infection. *Immunity* 52: 1039–1056.e9.
- 971 166. Brown, C. C., H. Gudjonson, Y. Pritykin, C. Leslie, D. Pe'er, and A. Y. Rudensky. 2019.  
972 Transcriptional Basis of Mouse and Human Dendritic Cell Heterogeneity In Brief Single-cell analyses  
973 of dendritic cells reveals new subsets with distinct pro-and anti-inflammatory potential. *Cell* 179:  
974 846–863.
- 975 167. Kamath, A. T., S. Henri, F. Battye, D. F. Tough, and K. Shortman. 2002. Developmental kinetics  
976 and lifespan of dendritic cells in mouse lymphoid organs. *Blood* 100: 1734–41.
- 977 168. Liu, K., C. Waskow, X. Liu, K. Yao, J. Hoh, and M. Nussenzweig. 2007. Origin of dendritic cells in  
978 peripheral lymphoid organs of mice. *Nat. Immunol.* 8: 578–583.
- 979 169. Auffermann-Gretzinger, S., L. Eger, M. Bornhäuser, K. Schäkel, U. Oelschlaegel, M. Schaich, T.  
980 Illmer, C. Thiede, and G. Ehninger. 2006. Fast appearance of donor dendritic cells in human skin:

- 981 Dynamics of skin and blood dendritic cells after allogeneic hematopoietic cell transplantation.  
982 *Transplantation* 81: 866–873.
- 983 170. Haniffa, M., F. Ginhoux, X. Wang, V. Bigley, M. Abel, I. Dimmick, S. Bullock, M. Grisotto, T.  
984 Booth, P. Taub, C. Hilkens, M. Merad, and M. Collin. 2009. Differential rates of replacement of  
985 human dermal dendritic cells and macrophages during hematopoietic stem cell transplantation. *J.  
986 Exp. Med.* 206: 371–85.
- 987 171. O'Keefe, M., H. Hochrein, D. Vremec, I. Caminschi, J. L. Miller, E. M. Anders, L. Wu, M. H.  
988 Lahoud, S. Henri, B. Scott, P. Hertzog, L. Tatarczuch, and K. Shortman. 2002. Mouse plasmacytoid  
989 cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into  
990 CD8(+) dendritic cells only after microbial stimulus. *J. Exp. Med.* 196: 1307–19.
- 991 172. Pelayo, R., J. Hirose, J. Huang, K. P. Garrett, A. Delogu, M. Busslinger, and P. W. Kincade. 2005.  
992 Derivation of 2 categories of plasmacytoid dendritic cells in murine bone marrow. *Blood* 105: 4407–  
993 15.
- 994 173. Ding, Y., C.-S. Chung, S. Newton, Y. Chen, S. Carlton, J. E. Albina, and A. Ayala. 2004.  
995 Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in  
996 mice. *Shock* 22: 137–44.
- 997 174. Efron, P. A., A. Martins, D. Minnich, K. Tinsley, R. Ungaro, F. R. Bahjat, R. Hotchkiss, M. Clare-  
998 Salzler, and L. L. Moldawer. 2004. Characterization of the systemic loss of dendritic cells in murine  
999 lymph nodes during polymicrobial sepsis. *J. Immunol.* 173: 3035–43.
- 1000 175. Gautier, E. L., T. Huby, F. Saint-Charles, B. Ouzilleau, M. J. Chapman, and P. Lesnik. 2008.  
1001 Enhanced Dendritic Cell Survival Attenuates Lipopolysaccharide-Induced Immunosuppression and  
1002 Increases Resistance to Lethal Endotoxic Shock. *J. Immunol.* 180: 6941–6946.
- 1003 176. Grimaldi, D., S. Louis, F. Pène, G. Sirgo, C. Rousseau, Y. E. Claessens, L. Vimeux, A. Cariou, J. P.  
1004 Mira, A. Hosmalin, and J. D. Chiche. 2011. Profound and persistent decrease of circulating dendritic  
1005 cells is associated with ICU-acquired infection in patients with septic shock. *Intensive Care Med.* 37:  
1006 1438–1446.
- 1007 177. Guisset, O., M.-S. Dilhuydy, R. Thiébaut, J. Lefèvre, F. Camou, A. Sarrat, C. Gabinski, J.-F.  
1008 Moreau, and P. Blanco. 2007. Decrease in circulating dendritic cells predicts fatal outcome in septic  
1009 shock. *Intensive Care Med.* 33: 148–152.
- 1010 178. Poehlmann, H., J. C. Schefold, H. Zuckermann-Becker, H.-D. Volk, and C. Meisel. 2009.  
1011 Phenotype changes and impaired function of dendritic cell subsets in patients with sepsis: a  
1012 prospective observational analysis. *Crit. Care* 13: R119.
- 1013 179. Riccardi, F., M. G. Della Porta, B. Rovati, A. Casazza, D. Radolovich, M. De Amici, M. Danova, and  
1014 M. Langer. 2011. Flow cytometric analysis of peripheral blood dendritic cells in patients with severe  
1015 sepsis. *Cytom. Part B Clin. Cytom.* 80B: 14–21.
- 1016 180. Jardine, L., S. Wiscombe, G. Reynolds, D. McDonald, A. Fuller, K. Green, A. Filby, I. Forrest, M.-H.  
1017 Ruchaud-Sparagano, J. Scott, M. Collin, M. Haniffa, and A. J. Simpson. 2019. Lipopolysaccharide  
1018 inhalation recruits monocytes and dendritic cell subsets to the alveolar airspace. *Nat. Commun.* 10:  
1019 1999.
- 1020 181. Vitorakis, S., K. Samitas, S. Tousa, E. Zervas, M. Aggelakopoulou, M. Semitekolou, V.  
1021 Panoutsakopoulou, G. Xanthou, and M. Gaga. 2014. Circulating conventional and plasmacytoid  
1022 dendritic cell subsets display distinct kinetics during in vivo repeated allergen skin challenges in  
1023 atopic subjects. *Biomed Res. Int.* 2014.
- 1024 182. Pasquevich, K. A., K. Bieber, M. Günter, M. Grauer, O. Pötz, U. Schleicher, T. Biedermann, S.

- 1025 Beer-Hammer, H.-J. J. Bühring, H.-G. G. Rammensee, L. Zender, I. B. Autenrieth, C. Lengerke, and S.  
1026 E. Autenrieth. 2015. Innate immune system favors emergency monopoiesis at the expense of DC-  
1027 differentiation to control systemic bacterial infection in mice. *Eur. J. Immunol.* 45: 2821–2833.
- 1028 183. Toliver-Kinsky, T. E., W. Cui, E. D. Murphey, C. Lin, and E. R. Sherwood. 2005. Enhancement of  
1029 Dendritic Cell Production by Fms-Like Tyrosine Kinase-3 Ligand Increases the Resistance of Mice to a  
1030 Burn Wound Infection. *J. Immunol.* 174: 404–410.
- 1031 184. Pillay, J., I. Den Braber, N. Vrisekoop, L. M. Kwast, R. J. De Boer, J. A. M. Borghans, K. Tesselaar,  
1032 and L. Koenderman. 2010. In vivo labeling with  $^{2}\text{H}_2\text{O}$  reveals a human neutrophil lifespan of 5.4  
1033 days. *Blood* 116: 625–627.
- 1034 185. Merad, M., M. G. Manz, H. Karsunky, A. Wagers, W. Peters, I. Charo, I. L. Weissman, J. G. Cyster,  
1035 and E. G. Engleman. 2002. Langerhans cells renew in the skin throughout life under steady-state  
1036 conditions. *Nat. Immunol.* 3: 1135–1141.
- 1037 186. Askew, K., K. Li, A. Olmos-Alonso, F. Garcia-Moreno, Y. Liang, P. Richardson, T. Tipton, M. A.  
1038 Chapman, K. Riecken, S. Beccari, A. Sierra, Z. Molnár, M. S. Cragg, O. Garaschuk, V. H. Perry, and D.  
1039 Gomez-Nicola. 2017. Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia  
1040 in the Adult Brain. *Cell Rep.* 18: 391–405.
- 1041 187. Murphy, J., R. Summer, A. A. Wilson, D. N. Kotton, and A. Fine. 2008. The prolonged life-span of  
1042 alveolar macrophages. *Am. J. Respir. Cell Mol. Biol.* 38: 380–385.
- 1043 188. Pallett, L. J., A. R. Burton, O. E. Amin, S. Rodriguez-Tajes, A. A. Patel, N. Zakeri, A. Jeffery-Smith,  
1044 L. Swadling, N. M. Schmidt, A. Baiges, A. Gander, D. Yu, D. Nasralla, F. Froghi, S. Iype, B. R. Davidson,  
1045 D. Thorburn, S. Yona, X. Forns, and M. K. Maini. 2020. Longevity and replenishment of human liver-  
1046 resident memory T cells and mononuclear phagocytes. *J. Exp. Med.* 217.
- 1047 189. Bujko, A., N. Atlasy, O. J. B. Landsverk, L. Richter, S. Yaqub, R. Horneland, O. Øyen, E. M.  
1048 Aandahl, L. Aabakken, H. G. Stunnenberg, E. S. Bækkevold, and F. L. Jahnsen. 2018. Transcriptional  
1049 and functional profiling defines human small intestinal macrophage subsets. *J. Exp. Med.* .
- 1050 190. De Schepper, S., S. Verheijden, J. Aguilera-Lizarraga, M. F. Viola, W. Boesmans, N. Stakenborg, I.  
1051 Voytyuk, I. Smidt, B. Boeckx, I. Dierckx de Casterlé, V. Baekelandt, E. Gonzalez Dominguez, M. Mack,  
1052 I. Depoortere, B. De Strooper, B. Sprangers, U. Himmelreich, S. Soenen, M. Guilliams, P. Vanden  
1053 Berghe, E. Jones, D. Lambrechts, and G. Boeckxstaens. 2018. Self-Maintaining Gut Macrophages Are  
1054 Essential for Intestinal Homeostasis. *Cell* 175: 400-415.e13.
- 1055 191. Bajpai, G., C. Schneider, N. Wong, A. Bredemeyer, M. Hulsmans, M. Nahrendorf, S. Epelman, D.  
1056 Kreisel, Y. Liu, A. Itoh, T. S. Shankar, C. H. Selzman, S. G. Drakos, and K. J. Lavine. 2018. The human  
1057 heart contains distinct macrophage subsets with divergent origins and functions. *Nat. Med.* 24:  
1058 1234–1245.
- 1059 192. Molawi, K., Y. Wolf, P. K. Kandalla, J. Favret, N. Hagemeyer, K. Frenzel, A. R. Pinto, K. Klapproth,  
1060 S. Henri, B. Malissen, H.-R. Rodewald, N. A. Rosenthal, M. Bajenoff, M. Prinz, S. Jung, and M. H.  
1061 Sieweke. 2014. Progressive replacement of embryo-derived cardiac macrophages with age. *J. Exp.*  
1062 *Med.* 211: 2151–8.
- 1063
- 1064